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In most patients suffering from end stage renal disease, renal transplantation is
the preferred treatment option, resulting in improved quality of life and reduced
mortality compared to either hemodialysis or peritoneal dialysis.1 During the past
three decades, improved immunosuppression has resulted in reduced acute
rejection rates and improved early allograft survival. However, it was not until
recently that this improvement in short-term results could be translated into an
increase in long-term renal graft survival. In the United States the current half-life
for grafts from cadaveric donors is 14 years (19 years after censoring for death),
and for grafts from living-related donors 22 years (36 years after censoring for
death).2 Death with functioning graft and chronic allograft nephropathy (CAN) are
the most frequently encountered causes of late allograft failure, followed by
recurrence of the original renal disease. 
Death with a functioning graft
Death with a functioning graft is a major cause of renal allograft failure, accounting
for 40% of graft losses in the first decade after transplantation.3 Stroke, myocardial
infarction and other cardiac events account for 35-50% of deaths.3-5 Mortality rates
from cardiovascular disease among renal transplant recipients are increased in all
age groups when compared with the general population.5 For example, in the age
group of 55 to 64 years, the risk of death from ischemic heart disease is 6.4 times
higher in nondiabetic and 20.8 times higher in diabetic renal transplant recipients
compared with the general population.4 Risk factors such as age, cholesterol, blood
pressure, and smoking that are associated with ischemic heart disease in the general
population also apply in the renal transplant population. Notably, the risk associated
with diabetes mellitus is particularly increased in the renal transplant population,
twofold in male and threefold in female patients.6
Lipid abnormalities are seen in approximately 80% of renal transplant patients.7
Elevated total and LDL cholesterol occur in about 60% of patients, and
hypertriglyceridemia in about 35%. A low HDL cholesterol is seen in about 15% of
renal transplant recipients.8 The lipoprotein profile can become more atherogenic
with triglyceride-rich small dense LDL cholesterol particles, that are more susceptible
for oxidation.9 Lipoprotein(a) is a risk factor for atherosclerotic vascular disease
and is associated with inhibited fibrinolysis. Lp(a) is often elevated in patients with
renal disease. Several immunosuppressive drugs, especially corticosteroids,
calcineurin inhibitors and sirolimus, contribute to the dyslipidemia.
Evidence from the general population indicates that treatment of dyslipidemias
reduces the risk of cardiovascular disease. In renal transplant patients statins result
8
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in improved cardiovascular risk markers. However, in a single large prospective
randomized trial in renal transplant patients, treatment with fluvastatin did not
significantly affect the composite endpoint of a major adverse cardiac event,
although significant reductions in secondary endpoints (cardiac death alone or in
conjunction with non-fatal myocardial infarction) were found.10
Since the introduction of cyclosporine, 70 to 90% of renal transplant patients have
hypertension.11;12 Hypertension is one of the most powerful predictors of
cardiovascular disease in the general population as well as in the renal transplant
recipients,13 and is also associated with the development and progression of CAN.14
Factors influencing posttransplantation hypertension are presence of host kidneys,
original renal disease, blood pressure prior to transplantation, rejection episodes,
renal graft function, and the use of corticosteroids and calcineurin inhibitors.11;15-17
Among all renal transplant patients diabetic patients have the highest rates of
cardiovascular morbidity and mortality. The incidence of posttransplant diabetes
mellitus ranges between 3.6 and 18%.18-20 High trough levels of cyclosporine or
tacrolimus, sustained exposure to corticosteroids and African-American recipient
race have been associated with an increased incidence of posttransplant diabetes
mellitus.19
The metabolic risk factor syndrome with obesity, hypertension, disturbed glucose
metabolism, lipid abnormalities and impaired fibrinolysis21 is frequently encountered
in renal transplant patients, and is strongly associated with cardiovascular disease.
In addition to the abovementioned well known traditional risk factors, several other
parameters have been identified in renal transplant patients that are associated
with atherosclerotic vascular disease. These risk factors are related to renal disease
or renal dysfunction, and include hyperhomocysteinemia, proteinuria, hyperuricemia,
left ventricular hypertrophy, hyperparathyroidism, hypercalcemia and
hyperphosphatemia.12 Prolonged dialysis treatment is associated with increased
coronary calcification,22 and time on dialysis is a risk factor for cardiovascular disease
after renal transplantation.23
Chronic allograft nephropathy
After death with functioning graft, chronic allograft nephropathy (CAN) is the most
common cause of graft failure beyond the early posttransplantation period,
accounting for up to 40% of graft losses. The clinical picture of CAN consists of
progressive renal insufficiency, hypertension and proteinuria, and the renal graft
9
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biopsy shows obliterative vasculopathy, glomerulosclerosis and interstitial fibrosis
with tubular atrophy. Transplant glomerulopathy, with splitting of the glomerular
basement membrane, may be seen.24 In recent studies, the incidence of the earliest,
mild histopathologic changes in protocol biopsies ranged from 67% to 94% within
two years after transplantation.25;26
Both immunologic and nonimmunologic factors are implicated in the pathogenesis
of CAN. The risk of CAN is associated with acute rejections, especially if they are
multiple, vascular or if they occur late after transplantation.27-29 Other immunologic
risk factors are inadequate immunosuppression,30;31and increased number of HLA
mismatches.32 Non-immunologic risk factors include donor-related damage to the
kidney (pre-existent vascular and glomerular damage), ischemia-reperfusion
damage and insufficient renal mass related to the metabolic demand of the recipient,
resulting in hypertrophy and hyperfiltration, and subsequent sclerosis of the
nephrons.33;34 The pathogenesis of CAN, especially the vasculopathy, shares many
features with the pathogenesis of systemic atherosclerosis. Indeed, known risk
factors for cardiovascular disease, like hypercholesterolemia, hypertriglyceridemia
and hypertension, are independent risk factors for CAN.35;36
Of special concern is the contribution of the calcineurin inhibitors to the development
of CAN. Calcineurin inhibitors have added greatly to the reduction in acute rejections
after solid organ transplantation. The use of calcineurin inhibitors is however
hampered by several side-effects, including acute and chronic nephrotoxicity,
hypertension and hyperlipidemia, thereby increasing the risk for the development
of graft failure and for cardiovascular disease. Although chronic calcineurin inhibitor
nephrotoxicity has some specific histologic features, consisting of striped interstitial
fibrosis, tubular microcalcifications and nodular hyaline deposition in the periphery
of the arterioles,24 differentiation between chronic rejection and chronic calcineurin
inhibitor nephrotoxicity on either clinical or histological grounds can be difficult.
Moreover, the picture is often complicated by the fact that both conditions can co-
exist in the same patient.
Attempts to reduce calcineurin inhibitor nephrotoxicity by lowering the cyclosporine
dose have resulted in an increased incidence of CAN,30;37 whereas targeting the
cyclosporine blood level within a narrow therapeutic window may help to maintain
a stable renal graft function.38
10
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Recurrent glomerulonephritis
Glomerulonephritis is the primary cause of end-stage renal failure in 20-40% of
patients receiving a donor kidney. Recurrent glomerulonephritis in the renal allograft
can result in clinical symptoms including proteinuria and reduced graft function.
In focal segmental glomerulosclerosis (FSGS), anti-GBM-glomerulonephritis, ANCA-
associated vasculitis, systemic sclerosis and the hemolytic uremic syndrome, clinical
symptoms and histological signs of recurrence usually occur concomitantly.  In many
other cases however, recurrent glomerulonephritis does not lead to clinical
symptoms and can only be diagnosed in routine biopsies. Dense deposit disease,
IgA nephropathy, and possibly SLE-nephritis are examples of diseases that recur
frequently without clinical signs.
Recurrent glomerulonephritis has been reported in 6.0 to 19.4% of renal transplant
patients, resulting in allograft loss in 1.1 to 8.4% of transplant recipients.39-43 The
variation in the reported incidence of recurrent glomerulonephritis and the
subsequent risk of graft loss, is related to the diagnostic criteria that were used,
the duration of follow-up, and the study population. The Renal Allograft Disease
Registry data show that the incidence of recurrent disease (glomerulonephritis and
metabolic diseases) increases from 2.8% at two years, to 9.8% at five years and
18.5% at eight years post-transplantation.39 Thus, as allografts last longer, the
relative importance of recurrence as the cause of allograft loss is likely to increase.
In fact, recurrent disease is the major cause of graft failure in recipients of an HLA-
identical living-related donor graft.44
In table 1, the incidence of histological and clinical recurrence of the most commonly
encountered glomerulonephritides and the impact on graft survival are summarized. 
In summary
Long-term renal graft survival is markedly affected by premature death with a
functioning graft, chronic allograft nephropathy, and recurrence of the original
kidney disease. Hypertension, hyperlipidemia and diabetes mellitus are frequently
encountered after renal transplantation and contribute to the high incidence of
cardiovascular disease and to the decline of graft function. The widely used
calcineurin inhibitors play a dual role since they have direct nephrotoxic effects,
and in addition are associated with the occurrence of hypertension, hyperlipidemia
and diabetes mellitus. However, the two clinically used calcineurin inhibitors,
cyclosporine and tacrolimus, may differ in these aspects.
11
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To improve long-term graft survival, focus is shifting from the prevention of acute
rejections to the recognition and treatment of other modifiable post-transplantation
risk factors for cardiovascular disease and progression of renal dysfunction. This
includes reducing the use of calcineurin inhibitors to avoid nephrotoxicity and to
improve the cardiovascular risk profile. However, evidence-based treatment aiming
at increasing graft survival and reducing cardiovascular death in renal transplant
patients is hard to prescribe because there is a lack of prospective randomized trials
with an adequate duration of follow-up.
Outline of the thesis
This thesis consists of three parts, all addressing issues that are of importance in
maintaining renal graft function. 
12
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Table 1. Incidence of recurrent glomerulonephritis after first renal transplantation.
histological
recurrence
(%)
clinical
recurrence
(%)
failure
rate a
(%)
refe-
rences
IgA nephropathy 26-58 % 9-20 % 10-26% 62-65
FSGS § 20-30 % 40-50 % 52;66;67
MGN 26-29% 10-29 % 50-60 % 40;68-71
MPGN I § 20-33 % 40 % 72;73
MPGN II (DDD) 80-100 % 5-29 % 50-100 %b       70;74;75
Lupus nephritis 30-50 %c <1 – 8 % # 70;76-78
Anti-GBM GN § <10 %d # 70;72
ANCA-associated systemic vasculitis § 10-40% # 79
ANCA-associated renal-limited vasculitis § <10% # 80
Systemic sclerosis § 20 % # 70
HUS § 10 – 60 % 40 – 100 % 81-84
a: patients with failure due to recurrence expressed as percentage of patients with clinical recurrence; b: failure rate
high especially if extracapillary proliferation; c: in light microscopy recurrence rate is low (< 10%), higher rate of
recurrence has been suggested by EM investigation and observation of tubulo-reticular inclusions in endothelial cells;
d: if transplanted after anti-GBM antibodies have been negative for more than 6 months; FSGS: focal segmental
glomerulosclerosis; MGN: membranous glomerulonephritis; MPGN: membrano-proliferative glomerulonephritis;
DDD: dense deposit disease; anti-GBM GN: anti-glomerular basement membrane glomerulonephritis; ANCA: anti-
cytoplasmatic antibodies; HUS: hemolytic uremic syndrome; #: number of cases too limited to permit conclusions; §:
incidence of clinically silent, histological recurrence is low, no exact data available.
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In part one, the results of the TACTICS trial are presented. In this prospective,
randomized, multicenter trial, the effects of conversion from cyclosporine to
tacrolimus in long-term renal transplant patients on renal graft function,
cardiovascular risk profile and side-effects were investigated. Calcineurin inhibitors
have resulted in a reduction in the incidence of acute rejections after renal
transplantation. However, as mentioned above, their use is associated with
nephrotoxicity, hypertension and dyslipidemia. Reduction of the dose of calcineurin
inhibitors or withdrawal from a regimen including cyclosporine, prednisone, and
either azathioprine or mycophenolate mofetil resulted in acute rejection in 10-
40%.45-47 In addition, lowering the cyclosporine dose has resulted in an increased
incidence of CAN.30;37 Since reduced dosing or withdrawal of cyclosporine results
in a significant risk of acute rejection and CAN, the question arises whether
conversion from cyclosporine to tacrolimus in stable chronic renal transplant patients
can result in improvements in renal function and cardiovascular risk factors without
risking acute rejection. Although tacrolimus and cyclosporine both are calcineurin
inhibitors, their mechanism of action as well as their side-effects are not entirely
comparable. Both cyclosporine and tacrolimus result in increased synthesis of the
fibrogenic cytokine transforming growth factor TGF-β1 (TGF-β), that has been
implicated as a key factor in the pathogenesis of chronic calcineurin inhibitor
nephropathy.48;49 However, several studies have shown that on tacrolimus the
production of TGF-β was less upregulated, suggesting that tacrolimus could be less
nephrotoxic than cyclosporine.50;51 Also, the effects of tacrolimus on blood pressure
and serum lipid levels appear to be less unfavourable, but evidence from controlled
studies is scarce. Data on the differential effects of cyclosporine and tacrolimus on
cardiovascular risk factors like the oxidizability of the LDL-particle, and the
homocysteine and fibrinogen levels are lacking. 
The second part of this thesis focuses on the recurrence of the original renal disease
in the renal allograft. Specifically, we have studied the outcome of renal
transplantation in patients suffering from end-stage renal disease due to lupus
nephritis, pauci-immune small vessel vasculitis, anti-glomerular basement
membrane (GBM)-glomerulonephritis, and the hemolytic uremic syndrome, with
emphasis on recurrent glomerulonephritis. 
Furthermore, we have performed an observational study to determine the pattern
of proteinuria due to ischemia-reperfusion damage, during the first days after living-
donor kidney transplantation. In focal segmental glomeruloscerosis (FSGS),
recurrence can occur very early after transplantation and is characterized by the
abrupt onset of severe proteinuria.52 If instituted soon after the initial presentation
of proteinuria, plasma exchange is effective in reducing proteinuria and results in
improved graft survival.52-54 When proteinuria develops within the first days after
13
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transplantation, it is important to differentiate between proteinuria due to ischemia-
reperfusion damage and proteinuria due to recurrent FSGS. However, data on the
time-course of proteinuria due to ischemia-reperfusion damage after living-donor
kidney transplantation are lacking. Knowledge of this pattern of proteinuria  should
enable us to make an adequate and early diagnosis of recurrent FSGS, thus allowing
to  start treatment as soon as possible.  
In the third part of this thesis, factors influencing graft survival in patients with
histologically diagnosed chronic allograft nephropathy (CAN) are investigated, with
special emphasis on the effect of blockade of the renin-angiotensin system (RAS).
RAS blockade results in reduced systemic and glomerular capillary blood pressure,
thereby reducing glomerular hyperfiltration and proteinuria. Treatment with
angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers
(ARB) reduces progression in diabetic and non-diabetic proteinuric renal disease
of native kidneys.55-58 The beneficial effect of RAS blockade in CAN has been
demonstrated in animal models,59;60 but data on the effect of RAS blockade in renal
transplant patients with CAN are scarce and non-conclusive.61
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Abstract 
Cyclosporine is considered to contribute to the high cardiovascular morbidity and
mortality in patients after renal transplantation. Tacrolimus may be more favorable
in this respect, but controlled data are scarce. In this prospective randomized study
in 124 stable renal transplant patients, we investigated the effects of conversion
from cyclosporine to tacrolimus on cardiovascular risk factors and renal function.
Follow-up was six months. Statistical analysis was performed by ANOVA for repeated
measurements. The serum creatinine level decreased from 137 ± 30 µmol/l to 131
± 29 µmol/l (p<0.01). Three months after conversion from cyclosporine to
tacrolimus, mean blood pressure significantly decreased from 104 ± 13 to 99 ±
12 mm Hg (p<0.001). Serum LDL cholesterol decreased from 3.48 ± 0.80 to 3.11
± 0.74 mmol/l (p<0.001) and serum apolipoprotein B decreased from 1018 ± 189
to 935 ± 174 mg/l (p<0.001). Serum triglycerides decreased from 2.11 ± 1.12 to
1.72 ± 0.94 mmol/l (p<0.001). In addition, both rate and extent of LDL oxidation
were reduced. The fibrinogen level decreased from 3638 ± 857 to 3417 ± 751 mg/l
(p<0.05). Plasma homocysteine concentration did not change. Three months after
conversion, plasma fasting glucose level temporarily increased from 5.4 ± 1.3
mmol/l to 5.8 ± 1.9 mmol/l (p<0.05). Conversion to tacrolimus resulted in a
significant reduction of the Framingham risk score. In conclusion, conversion from
cyclosporine to tacrolimus in stable renal transplant patients has a beneficial effect
on renal function, blood pressure, serum concentration and atherogenic properties
of serum lipids, and fibrinogen.
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Introduction
During the past two decades, cyclosporine has proven to be a valuable
immunosuppressive drug that has contributed to a significant reduction in the
incidence of acute rejection after renal transplantation. However, cyclosporine also
increases cardiovascular risk profiles.1 Ultimately up to 63 % of renal transplant
patients die of cardiovascular disease.2 The increased cardiovascular risk profile
due to cyclosporine is ascribed to both a quantitative increase in low-density
lipoprotein (LDL)- particles and to an increased oxidizability of the LDL particles.3-5
Use of cyclosporine is also associated with increased plasma lipoprotein(a) (Lp(a))6
and homocysteine levels7, but these effects are not unequivocal.8 In addition,
unfavorable effects on the fibrinolytic system by cyclosporine have been described.9
Apart from these disadvantageous effects of cyclosporine on several metabolic
cardiovascular risk factors, cyclosporine also leads to an elevation of blood
pressure.4 These side effects not only contribute to the high cardiovascular morbidity
in renal transplant patients, but they may also lead to an accelerated loss of graft
function.10-12
Tacrolimus is like cyclosporine a calcineurin inhibitor with even more potent
immunosuppressive properties. The use of tacrolimus after renal transplantation
is associated with a less unfavorable effect on blood pressure and serum lipid levels,
but evidence from controlled studies is scarce.4;13 Little is known about the
differential effects of cyclosporine and tacrolimus on established cardiovascular risk
factors like homocysteine, oxidizability of LDL-particles, and fibrinogen levels. In
the present study, we investigated the effect of conversion from cyclosporine to
tacrolimus in renal transplant patients on the cardiovascular risk profile and on
graft function in a multicenter prospective randomized design.
Materials and Methods
Patients
To be eligible for the study the patients had to be at least one year
posttransplantation with a stable endogenous creatinine clearance exceeding 20
ml/min. Immunosuppressive treatment at enrollment had to include cyclosporine
with trough levels ranging from 50 to 200 ng/ml, and prednisone, with or without
azathioprine or mycophenolate mofetil. 
Study Protocol
This prospective randomized open-label study was performed in four renal
transplant centers. After stratification for center, patients were randomized in a
21
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1:1-fashion to either continuation of cyclosporine or conversion to tacrolimus. Total
follow-up was 6 months. Evaluation took place at baseline and after three and six
months. Target drug trough levels were 50 to 200 ng/ml for cyclosporine and 5 to
8 ng/ml for tacrolimus. Lipid-lowering drug treatment and antihypertensive
treatment preferably remained unchanged. Adjustment of lipid-lowering medication
was allowed when the serum total cholesterol level was below 4.0 mmol/l or
exceeded 6.5 mmol/l, or when the serum triglyceride level exceeded 4.0 mmol/l.
Changes in antihypertensive medication were allowed when the systolic blood
pressure was >160 mm Hg or <120 mm Hg, or when the diastolic blood pressure
was >90 mm Hg or <70 mm Hg. Blood pressure was measured in supine position
manually after 5 minutes of rest in all participating patients. In patients from three
out of four participating centers, blood pressure was also measured using an
automated device (Dinamap, Critikon Inc., Tampa, USA) during 30 minutes. The
diagnosis of diabetes mellitus was based on the fasting glucose levels, with a cut-
off value of 7.0 mmol/l, measured on two separate occasions, in accordance with
the American Diabetes Association criteria.14 Framingham risk scores were
calculated using age, smoking behavior, the presence of diabetes mellitus, fasting
LDL and HDL cholesterol levels and the systolic and diastolic blood pressure.15 The
study was approved by the medical ethics committee of each participating center.
All patients gave written informed consent.
Laboratory Procedures
All blood was drawn after an overnight fast, during morning hours in sitting position.
The blood sample for determination of the parameters of fibrinolysis was drawn
after releasing the tourniquet to avoid hemolysis. 
Serum lipids and lipoproteins (by a combined ultracentrifugation – precipitation
method), Lp(a) (by a commercially available radioimmunoassay) and total
apolipoprotein B (by immunonephelometry) were determined as described before.16
The oxidizability of LDL was determined at baseline and after three months of follow-
up by registration of the 234 nm absorbance of dienes produced by copper added
to isolated LDL.17 Both EDTA-plasma samples of each person were stored at -80°C
(with 10 µl 600 g/l saccharose-solution per ml plasma as cryoprotectant) and
analyzed in the same assay. The sample for determination of plasma homocysteine
was placed on ice until centrifugation and frozen storage. The plasma homocysteine
concentration was measured using a high-performance liquid chromatography
procedure, with reverse phase separation and fluorescence detection.18 Antigen
levels of the various components of the plasminogen activator system were
determined by ELISA.19 The cyclosporine level was determined in whole blood with
a fluorescence-polarization immune-assay (TDx/TDx FLx cyclosporine monoclonal
22
Chapter 2
bw.van leeuwen  12-07-2005  10:34  Pagina 22
whole blood assay, Abbott Laboratories, Chicago, IL, USA) and the tacrolimus level
was determined using a microparticle enzyme immune-assay (IMx Tacrolimus II
Assay, Abbott Laboratories). 
Statistical Analysis
Statistical analysis was performed using the Statistical Product and Services
Solutions (SPSS) package, version 9.0. Values are given as mean ± standard
deviation in case of a normal distribution or otherwise as median and interquartile
range. Statistical analysis was performed using one-way ANOVA for repeated
measurements. If the ANOVA revealed a statistically significant difference, post
hoc comparisons were performed using Bonferroni‘s correction for multiple
comparisons. 
For parameters that were only determined at two time-points, Student’s t-test was
used in case of normal distribution and otherwise Wilcoxon signed ranks test was
used. For correlations, Pearson’s product moment correlation coefficient was used
and for analysis of proportions Fisher’s exact test was applied. Results are analyzed
on an intention-to-treat base for renal function and blood pressure, whereas the
metabolic parameters are analyzed in the patients who remained on study
medication during follow-up. A p-value of less than 0.05 was considered statistically
significant. 
Results
Between February 1999 and September 2000, 124 patients were included in the study.
Baseline characteristics are shown in Table 1. Sixty-four patients were converted to
tacrolimus (conversion group) and 60 patients remained on cyclosporine (control
group). There were no baseline differences between both groups in serum creatinine
level, blood pressure, or any metabolic parameter. Mean baseline cyclosporine trough
level was 129 ± 42 ng/ml in the control group versus 130 ± 42 ng/ml in the conversion
group (n.s.). In the control group, the cyclosporine trough level remained unchanged
during follow-up. In the conversion group, the mean tacrolimus trough level was 7.4
± 1.8 ng/ml after three months and 7.4 ± 1.9 ng/ml after six months of follow-up.
Baseline prednisone dose was 0.10 ± 0.04 mg/kg in the conversion group and 0.10
± 0.04 mg/kg in the control group, baseline azathioprine dose was 0.88 ± 0.40 mg/kg
(n=10) in the conversion group and 0.95 ± 0.47 mg/kg (n=15) in the control group.
In the control group two patients used mycophenolate mofetil 2000 mg/day. The
dosages of prednisone, azathioprine and mycophenolate mofetil remained unchanged
throughout the study period.
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In the control group, two patients died, one of a cardiac event and one of sepsis.
In this group, a further three patients were withdrawn from the study for the
following reasons: patient’s wish to switch to tacrolimus, patient’s wish to stop
prednisone and one patient lost to follow-up. In the conversion group, one patient
died of a cardiac event. In this group, six patients were withdrawn from the study,
due to worsening of preexistent diabetes mellitus (n=1), new-onset diabetes
mellitus (n=1), headache (n=2), allergic skin reaction to tacrolimus (n=1), and
progression of preexistent proteinuria (n=1). A renal graft biopsy in the latter
patient, taken four months after conversion to tacrolimus, showed signs of chronic
allograft nephropathy. 
24
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Table 1 Baseline patient demographics
cyclosporine
(n=60)
tacrolimus
(n=64)
Time after RTX (years) 6.6 ± 3.7 5.7 ± 2.7
Gender (m/f)                                                                                   34/26 41/23
Age (years) 50 ± 13 50 ± 14
Race caucasian 57 (95%) 60 (94%)
black 0 0
other 3 (5%) 4 (6%)
Original renal disease chronic glomerulonephritis 17 (28%) 20 (31%)
chronic pyelonephritis 5 (8%) 11 (17%)
polycystic kidney disease 13 (22%) 13 (20%)
diabetic nephropathy 3 (5%) 1 (2%)
otherwise 19 (32%) 17 (27%)
unknown 3 (5%) 2 (3%)
Diabetes mellitus type 1 5 (8%) 2 (3%)
type 2 3 (5%) 6 (9%)
Mean ± SD; no significant differences. RTX: renal transplantation.
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Renal Function and Blood Pressure
After conversion from cyclosporine to tacrolimus, no acute rejections occurred. After
six months of follow-up, conversion from cyclosporine to tacrolimus resulted in a
significant decrease in the serum creatinine level from 137 ± 30 to 131 ± 29 µmol/l
(Table 2). Urinary protein excretion showed a small but significant increment in
the cyclosporine group, whereas it remained unchanged in the tacrolimus group.
At three months of follow-up, the manually measured systolic and diastolic blood
pressure were significantly decreased in the tacrolimus group from 144 ± 21 mmHg
to 138 ± 18 mmHg and 84 ± 12 mmHg to 80 ± 11 mmHg, respectively (Table 2).
These changes were no longer significant after 6 months of follow-up. These results
did not change when only patients that remained on study medication during follow-
up were analyzed. 
Lipid Profile
After conversion from cyclosporine to tacrolimus, serum total and LDL cholesterol,
triglycerides, and apolipoprotein B levels decreased, whereas HDL cholesterol and
Lp(a) level did not change (Table 3). Entering the use of a statin as a covariate,
revealed a significant influence of statin-usage on the change in LDL cholesterol
level after conversion. In the tacrolimus group, patients on statins had a lower
baseline LDL cholesterol level compared to patients not using statins (3.20 ± 0.60
mmol/l versus 3.86 ± 0.90 mmol/l, p<0.01), and there was no significant reduction
in LDL cholesterol level 6 months after conversion to tacrolimus in patients using
statins (0.22 ± 0.66 mmol/l, p=0.31 for comparison with baseline), compared to
a significant reduction in patients not using statins (0.65 ± 0.64 mmol/l, p<0.001
for comparison with baseline).  
At three months of follow-up, tacrolimus treated patients showed a significant
increase in the resistance to in vitro oxidation of the LDL-particles, as shown by an
increment in the lagtime for oxidation and decrements in the appearance-rate of
dienes and the total amount of diene-formation. The reduction in oxidizability of
the LDL-particle was not dependent on the concomitant use of statins. 
In two cyclosporine treated patients, statins were started and in one patient the
dosage was increased. In the tacrolimus group, the statin was stopped in one patient
and the dosage was reduced in another patient.
Glucose regulation
In the tacrolimus group, the plasma fasting glucose level showed an increase after
three months of follow-up. After six months of follow-up the glucose level was not
different from the baseline value (Table 4). When analyzing diabetic and non-diabetic
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patients separately, there were no significant changes in glucose level in either
group during follow-up. HbA1c levels were determined in one center (n=35) and
there were no significant changes after conversion to tacrolimus. When analyzing
diabetic and non-diabetic patients separately, again there were no significant
changes in HbA1c level in either group after conversion to tacrolimus.
Six months after conversion from cyclosporine to tacrolimus, four patients (6%)
had developed new-onset diabetes mellitus, versus two patients in the control group
(3%, n.s.). In the conversion group, the new-onset diabetes mellitus could be
treated with oral antidiabetic drugs in two cases and in the other two patients only
dietary measures were necessary, resulting in plasma fasting glucose levels
persistently below 6 mmol/l and a HbA1c below 6.1 %. Both patients that were
put on antidiabetic medication wanted to be taken off the tacrolimus and they were
converted from tacrolimus to azathioprine. No acute rejections occurred. In one
patient the oral antidiabetic medication could be stopped 4 months after withdrawal
of tacrolimus, in the second patient the oral antidiabetic medication was continued
in a low dosage. In three out of six tacrolimus-treated patients with pre-existent
type 2 diabetes mellitus, the dose of the oral antidiabetic medication had to be
increased, versus zero out of three patients in the control group. HbA1c level did
not change in either group during follow-up.
Other Metabolic Cardiovascular Risk Factors
Baseline homocysteine level correlated significantly with baseline serum creatinine
value (r= 0.43, p<0.001). During follow-up, there were neither changes in plasma
homocysteine levels (Table 4) nor in serum folic acid concentration (data not shown).
After conversion from cyclosporine to tacrolimus, the plasma fibrinogen level and
the plasma urokinase type plasminogen activator (uPA) level decreased. There were
no changes in the plasma levels of plasminogen activator inhibitor type I (PAI-I),
tissue type plasminogen (tPA) and tPA-PAI-complex (Table 4).
Framingham risk score
After conversion to tacrolimus a significant reduction of the Framingham risk score
was observed at 3 months of follow-up, but no longer at 6 months after conversion
(p=0.13). Entering the use of a statin as co-variate, revealed a significant influence
of statin-usage on the change in the Framingham risk score after conversion. In
the patients not using a statin, the framingham risk score significantly decreased
from 4.0 ± 6.1 to 2.6 ± 6.3 at 6 months (p<0.001), whereas in patients using a
statin the framingham risk score did not change (6.0 ± 4.1 at baseline and 6.1 ±
4.6 at 6 months, Fig 1.). 
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Discussion
The grossly enlarged cardiovascular risk in renal transplant patients is related to
a combination of partly related risk factors, such as hypertension, hyperlipidemia,
hereditary risk, diabetes mellitus, physical inactivity, obesity, hyperuricemia,
hyperhomocysteinemia and hyperparathyroidism. In order to address the pressing
challenge in renal transplantation of improving patient survival and long-term graft
function, this broad spectrum of risk factors has to be optimized, without putting
the graft function at risk. In this prospective randomized controlled trial, conversion
from cyclosporine to tacrolimus in stable renal transplant patients resulted in an
improvement in a number of cardiovascular risk factors, together with an
improvement  in renal function without risking acute rejection. 
After conversion to tacrolimus the serum LDL cholesterol level is reduced and the
LDL particles are less susceptible to oxidation. Cyclosporine increases serum LDL
cholesterol level by inhibiting the synthesis of LDL receptors in the liver, thereby
interfering with the LDL receptor mediated catabolism in the liver.20 The
improvement in serum LDL cholesterol level after conversion to tacrolimus might
be due to the withdrawal of this inhibition of the LDL receptor-production. However,
this quantitative improvement of LDL cholesterol is only achieved in patients not
treated with statins. In patients using statins, baseline LDL cholesterol already is
reduced and no further reduction is observed after conversion from cyclosporine
to tacrolimus, at least not in this subgroup with a limited number of patients. The
atherogenicity of LDL cholesterol not only depends on its serum concentration, but
also on the oxidizability of the particles.21 Therefore, it is important that conversion
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from cyclosporine to tacrolimus not only reduced the serum concentration of LDL
cholesterol, but also the oxidizability of the LDL-particle. Both the increment in the
lag time before initiation of oxidation of LDL and the lower rate of oxidation reflect
increased resistance of LDL against oxidation. This reduction in oxidizability occurred
both in patients with and without the use of statins, and therefore, conversion to
tacrolimus was beneficial for both patient groups. The reduced oxidizability of the
LDL-particles is likely to be associated with the concurrent decrease in serum
triglycerides after conversion to tacrolimus. Reduced levels of serum triglycerides
and apolipoprotein B are associated with an altered, less dense composition of the
LDL- particles.22 These lighter LDL-particles contain more lipids compared to the
protein component, resulting in conformational changes with a diminished access
for free radicals and pro-oxidants such as copper to cause oxidation of the fatty
acids.23 Indeed, the lipid-enriched lower-density LDL-subfractions have been
shown to be more resistant against oxidation.24 Furthermore, lighter LDL particles
are more easily cleared from the circulation by the high-affinity LDL-receptor, leading
to a shorter plasma residence time, during which the particle is susceptible to in-
vivo oxidation.25 In line with our findings, an increased lag time for oxidation in
patients on tacrolimus compared to patients on cyclosporine was recently
reported.26 In contrast, Varghese et al. reported that LDL from tacrolimus-treated
patients was more susceptible to oxidation compared to cyclosporine-treated
patients.27 However, in that cross-sectional study, the blood level of cyclosporine
was very low, averaging 87 ± 35 ng/ml, which is below the limit of 120 ng/ml above
which accelerated oxidation of isolated LDL was found.5
We previously showed that tacrolimus trough level reduction from 9.5 to 6.4 ng/ml
did not result in a reduction of total and LDL cholesterol and triglycerides28, which
makes it unlikely that the improvement in the serum lipid profile in our conversion
group is related to a relatively low level of tacrolimus in our patients. Also, it is
unlikely that the improvement in renal function in the conversion group can account
for the improvement in the lipid profile, since the lipid profile was already improved
at 3 months whereas renal function was only improved after 6 months. Also, there
was no correlation between the reduction in LDL cholesterol or in triglyceride levels
and the serum creatinine level after conversion to tacrolimus (data not shown). 
Diabetes mellitus is a major cardiovascular risk factor and is also associated with
an increased risk of developing graft failure.29 Although tacrolimus has been
reported to be diabetogenic,30;31 this risk is predominantly present in the initial
period after transplantation.32 After lowering the dose of tacrolimus and withdrawal
of steroids, most patients can be weaned off the diabetic medication.33 In this study,
performed in a population that predominantly consisted of Caucasian patients, only
a small and temporary increase in fasting glucose level was present at three months
after conversion. When analyzing diabetic and non-diabetic patients separately,
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there was no significant change in glucose level in either group during follow-up.
This could however be related to reduced power to detect a difference due to a
smaller population. We know from previous studies that tacrolimus influences
glucose metabolism by reducing pancreatic insulin secretion in a dose-dependent
way.28 Initially, also an increase in insulin resistance has been reported32, but this
is the result of the co-administration of steroids.28 At standard maintenance trough
levels, no difference between cyclosporine and tacrolimus could be determined with
regard to their diabetogenic properties.34 Therefore, in the majority of patients,
conversion from cyclosporine to tacrolimus is safe with regard to the development
of diabetes mellitus. The risk of developing diabetes mellitus after conversion to
tacrolimus is restricted to patients who already experience a disturbed glucose
tolerance prior to therapy, and might be increased in black and hispanic patients
who have a greater predisposition to develop posttransplant diabetes.30;32;35
In 77% of our patients, the fasting homocysteine level exceeded the advised upper
level of 15 µmol/l. An impaired renal function is supposed to be an important factor
contributing to hyperhomocysteinemia after renal transplantation7 and there are
conflicting data on the role of cyclosporine.7;8 Conversion from cyclosporine to
tacrolimus did not result in a significant reduction of the fasting homocysteine level.
The observed reduction in fibrinogen levels after conversion to tacrolimus might
also be important in reducing cardiovascular disease, since a high fibrinogen level
is an important and independent cardiovascular risk factor.36 Also, in a cross-
sectional study, high fibrinogen levels have been associated with chronic renal
allograft dysfunction.37 With regard to determinants of the fibrinolytic system, a
reduction in the level of the plasma uPA level was observed in the tacrolimus group.
The plasma levels of the other determinants of the fibrinolytic system remained
unchanged after conversion. UPA is not only involved in fibrinolysis, but also in
tissue remodeling during wound healing. High levels of uPA are associated with a
higher degree of restenosis after coronary artery angioplasty.38 There are however
no data indicating that reduction of the uPA level has a role in the primary prevention
of cardiovascular disease. 
The manually measured systolic and diastolic blood pressure were decreased at
three months after conversion from cyclosporine to tacrolimus by 7 ± 18 mm Hg
and 5 ± 10 mm Hg, respectively. In agreement with these findings, a recent study
in healthy volunteers showed that, in contrast to cyclosporine, tacrolimus did not
increase blood pressure.39 However, in the current study, the decline in blood
pressure tended to wane with time and was no longer significant at 6 months of
follow-up. Measurement of blood pressure with an automated device showed a
similar trend, although the differences did not reach statistical significance,
probably due to the smaller number of patients in whom the blood pressure was
determined automatically. No change in antihypertensive medication, nor in
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tacrolimus trough level occurred, that could account for the diminished effect of
conversion to tacrolimus on blood pressure after six months. 
The Framingham risk score was used in order to integrate the differential effects
of cyclosporine and tacrolimus on several important components of the
cardiovascular risk profile, namely serum lipids, blood pressure, and diabetes
mellitus. Conversion to tacrolimus resulted in a significant reduction of the
Framingham risk score. This reduction however was only apparent in patients not
using statins, indicating that reduction of the LDL cholesterol level is the main factor
influencing the risk score after conversion to tacrolimus. The Framingham risk score
was developed in an American population not suffering from specific underlying
diseases, and has been validated in several other geographic and ethnic
populations.40 Probably, renal transplant patients will benefit from a reduction of
the Framingham risk score. However, the risk score has never been validated in
patients suffering from renal disease and, since renal patients experience other
contributing pathogenic mechanisms, e.g. hyperparathyroidism and secundary
hyperlipidemia, characterized by hypertriglyceridemia and small dense LDL-
particles, it is unlikely that the prediction of the absolute risk of coronary heart
disease from the Framingham risk score can directly be applied to these patients.
Another drawback of this risk score is that it does not take into account several
more recently recognized cardiovascular risk factors, like the oxidizability of the
LDL particles and the fibrinogen level. 
The improvements in the cardiovascular risk profile as described above not only
are important for the cardiovascular morbidity and mortality, but also are likely to
be of benefit for long-term graft function. Chronic allograft nephropathy (CAN) is
the main cause of late graft loss in renal transplantation. The pathogenesis of CAN
is multifactorial. The initiating factors are probably mainly immunologic, while the
perpetuating factors are considered to be largely non-immunologic, including
hyperlipidemia and hypertension.41 Accordingly, increased levels of LDL cholesterol
and triglycerides are associated with the occurrence of CAN after renal
transplantation.11;42 Oxidatively modified LDL cholesterol is a chemotactic factor
for monocytes and macrophages, both in vascular endothelium and in renal
glomeruli and it may cause activation of endothelial cells, smooth muscle cells,
mesangial cells, and macrophages.43-45 Bosmans et al.10 showed deposition of LDL
and oxidized LDL in a mesangiocapillary way in the glomeruli, in endothelial cells,
and in the interstitial space. The amount of oxidized LDL immunostaining was related
to the increase in the density of macrophages in the tubulo-interstitial compartment
and to the extent of interstitial fibrosis.10 Therefore, the reduction of LDL-
cholesterol and the improvement of LDL-oxidation by tacrolimus may be of benefit
for long-term graft survival.
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Some studies report that tacrolimus as part of the initial maintenance
immunosuppressive therapy leads to a significantly improved long-term renal graft
survival compared to cyclosporine, but this effect of tacrolimus is not
unequivocal.31;46 In the analysis of Hariharan et al., tacrolimus was not a significant
factor contributing to the recently observed improvements in graft half-life.47
Possible mechanisms by which tacrolimus could induce an improvement in graft
survival include stronger immunosuppression leading to a reduction in the incidence
and severity of acute rejections30;31, differential effects on renal hemodynamics
leading to diminished renal vasoconstriction on tacrolimus39, a reduction in blood
pressure and serum lipid levels4 and a reduction in interstitial fibrosis inducing
cytokines like TGF-β.48 Based on this knowledge, it is of interest to see that
conversion from cyclosporine to tacrolimus in a later stage after renal
transplantation still can lead to an improvement in renal function. In view of the
improvement in renal function, the question arises whether equipotent dosages of
cyclosporine and tacrolimus have been used. In the participating centers, where
mainly patients from Caucasian origin are treated, the standard target tacrolimus
trough level after one year posttransplantation ranges from 5 to 8 ng/ml.49 Our
mean tacrolimus trough level was lower than the level that was achieved in several
previously performed long term studies, ranging from 8.5 ng/ml to approximately
12 ng/ml, but also our cyclosporine level was low compared to these studies, where
levels ranging from 174 ng/ml to approximately 180 ng/ml were achieved.30;50 Our
tacrolimus and cyclosporine trough levels were comparable with the levels in the
study of Mayer et al., who achieved mean trough levels of 7.3 ng/ml and 119 ng/ml
for tacrolimus and cyclosporine, respectively.31 In our population, the maintenance
tacrolimus dose was sufficient to prevent acute rejections in all patients. Longer
follow-up of our patients will disclose whether the improvement in graft function
is sustained. 
In conclusion, this study demonstrates that conversion from cyclosporine to
tacrolimus results in an improved cardiovascular risk profile, with regard to serum
levels as well as atherogenic properties of the lipid profile, the serum fibrinogen
level and blood pressure. Furthermore, renal function improves. These findings are
likely to be of importance in reducing the incidence of cardiovascular disease and
may benefit graft survival. The diabetogenic effect of tacrolimus was of clinical
relevance in a minor subset of patients, particularly those that already had an
impaired glucose tolerance prior to conversion to tacrolimus. Overall, when long-
term treatment with calcineurin inhibitors is required, tacrolimus is preferable to
cyclosporine for optimization of the cardiovascular risk profile and graft function,
except perhaps in patients known to have an impaired glucose tolerance.   
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Abstract
Long-term use of cyclosporine after renal transplantation results in nephrotoxicity
and an increased cardiovascular risk profile. Tacrolimus may be more favorable in
this respect. In this randomized controlled study in 124 renal transplant patients,
the effects of conversion from cyclosporine to tacrolimus on renal function,
cardiovascular risk factors, and perceived side-effects were investigated after a
follow-up of two years. 
After conversion from cyclosporine to tacrolimus renal function remained stable,
whereas continuation of cyclosporine was accompanied by a rise in serum creatinine
from 142 ± 48 µmol/l to 157 ± 62 µmol/l (p<0.05 comparing both groups).
Conversion to tacrolimus resulted in a sustained reduction in systolic and diastolic
blood pressure, and a sustained improvement in the serum lipid profile, leading to
a reduction in the Framingham risk score from 5.7 ± 4.3 to 4.8 ± 5.3 (p<0.05).
Finally, conversion to tacrolimus resulted in decreased scores for occurrence of and
distress due to side-effects.
In conclusion, conversion from cyclosporine to tacrolimus in stable renal transplant
patients is beneficial with respect to renal function, cardiovascular risk profile, and
side-effects. Therefore, for most renal transplant patients tacrolimus will be the
drug of choice when long-term treatment with a calcineurin inhibitor is indicated.
40
Chapter 3
bw.van leeuwen  12-07-2005  10:34  Pagina 40
Introduction
Cyclosporine and tacrolimus are calcineurin inhibitors that are very effective in
reducing the incidence of acute rejection after renal transplantation. However,
cyclosporine-induced side effects, including nephrotoxicity, hypertension, and
hyperlipidemia1 may contribute to the high cardiovascular morbidity in renal
transplant patients,2 and can also lead to an accelerated loss of graft function.3;4
Tacrolimus has also been associated with nephrotoxicity, but an increased graft
survival in patients using tacrolimus as initial immunosuppressive treatment has
been reported.5 Moreover, tacrolimus is associated with less hypertension and
hyperlipidemia, thereby improving the cardiovascular risk profile.1 However, a
drawback of tacrolimus is the increased risk of developing diabetes mellitus,6;7 which
could antagonize the beneficial effect of reduced blood pressure and improved
hyperlipidemia on the cardiovascular morbidity and mortality. 
Many of the renal transplant patients that have been transplanted in the past two
decades are using cyclosporine as maintenance immunosuppressive therapy. The
question arises whether conversion from cyclosporine to tacrolimus in these chronic
renal transplant patients will lead to an improved cardiovascular risk profile and
whether renal graft function still can be improved. 
In this prospective randomized controlled multi-center trial we compared the effects
of conversion from cyclosporine to tacrolimus in stable chronic renal transplant
patients on graft function and on the cardiovascular risk profile, expressed as the
Framingham risk score. Also, we assessed the patients’ perceived symptom
experience associated with side effects of the immunosuppressive therapy, using
the “modified transplant symptom occurrence and symptom distress scale”.8 The
changes in several metabolic parameters during the first six months after conversion
from cyclosporine to tacrolimus have been described in detail before.9 In this paper,
data on renal function, Framingham risk score, and side effects until the end of
follow-up, at two years after randomization, are presented. 
Materials and Methods
Patients
To be eligible for the study the patients had to be at least one year
posttransplantation with a stable endogenous creatinine clearance exceeding 20
ml/min. Immunosuppressive treatment at enrollment had to include cyclosporine
with trough levels ranging from 50 to 200 ng/ml and prednisone, either with or
without azathioprine or mycophenolate mofetil. 
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Study Protocol
The study protocol has been described before.9 In short, this prospective randomized
controlled open-label multicenter trial was performed in four renal transplant
centers. After stratification for center, patients were randomized to either
continuation of cyclosporine or conversion to tacrolimus. Total follow-up was 24
months. Evaluation took place at baseline, at three, six, 12 and 24 months. Target
drug trough levels were 50 to 200 ng/ml for cyclosporine and 5 to 8 ng/ml for
tacrolimus. Adjustment of lipid-lowering drug treatment and antihypertensive
treatment was only allowed under strict, predefined conditions. Blood pressure was
measured in supine position manually after 5 minutes of rest and also using an
automated device (Dinamap, Critikon Inc., Tampa, USA) during 30 minutes. The
diagnosis of diabetes mellitus was based on fasting glucose levels, with a cut-off
value of 7.0 mmol/l, measured on two separate occasions, in accordance with the
American Diabetes Association criteria.10
Framingham risk scores were calculated using baseline age, smoking behaviour,
the presence of diabetes mellitus, fasting LDL and HDL cholesterol levels and the
systolic and diastolic blood pressure.11 The study was approved by the medical ethics
committee of each participating center. All patients gave written informed consent.
Laboratory Procedures
All blood was drawn after an overnight fast. Plasma cholesterol and (fasting)
triglycerides were measured at a certified routine clinical chemistry laboratory on
a Hitachi 747 analyser using reagents of Roche (no’s: 337574 and 1361155,
respectively). Cyclosporine levels were determined in whole blood with a
fluorescence-polarization immune-assay (TDx/TDx FLx cyclosporine monoclonal
whole blood assay, Abbott laboratories, Chicago, IL, USA) and tacrolimus levels
were determined using a microparticle enzyme immune-assay (Imx Tacrolimus II
Assay, Abbott Laboratories). The endogenous creatinine clearance was calculated
using the creatinine excretion in a 24-hours urine sample.
Assessment of symptom experience
Symptom experience associated with side effects of the immunosuppressive therapy
was measured using the “Modified Transplant Symptom Occurrence and Distress
Scale” (MTSOSDS).8 This scale includes 38 symptoms associated with side effects
of immunosuppressive medication (tacrolimus, cyclosporine, prednisone and
azathioprine). The instrument measures symptom experience on a five-point rating
scale from 0 (never occurring) to 4 (always occurring) for symptom occurrence,
and from 0 (not at all distressing) to 4 (extremely distressing) for symptom distress,
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respectively. The following items were evaluated: acne, fragile skin, easy bruising,
warts, skin rash, increased hair growth, hair loss, gingival hyperplasia, moon face,
changed facial appearance, changed bodily appearance, swollen ankles, warmth
in hands and feet, headache, poor vision, light insensitivity, tremor, paraesthesias,
muscle weakness, muscle cramps, impotence / painful menstruation, decreased
interest in sex, depression, agitation, anxiousness, mood swings, poor
concentration, sleeplessness, hallucinations, nightmares, fatigue, increased
appetite, poor appetite, abdominal pain, stomach complaints, diarrhoea, dysuria
and back pain.  The initial 29-item version of this instrument has been validated
for the use in renal transplant patients.8 The content validity of the updated
instrument is based on a comprehensive literature review and has been tested by
an expert panel (data on file).
Statistical Analysis
Statistical Analysis was performed using the Statistical Product and Services
Solutions (SPSS) package, version 11.0. Values are given as mean ± standard
deviation in case of a normal distribution or otherwise as median and interquartile
range. For the serum lipids, blood pressure, glucose, HbA1c, and the Framingham
risk scores, the mean level during treatment was calculated for each patient by
dividing the area under the curve by the treatment duration, since the cardiovascular
risk is related to the cumulative exposure time to risk factors. For analysis of renal
function the value at the end of follow-up was used. Analysis of the serum creatinine
levels was performed after normalization by calculating the reciprocal value.
Statistical analysis was performed using ANCOVA. Independent factors were
randomization-group, baseline value, and in case of serum lipids the use of a statin
at baseline. Categorical values were analyzed using the chi-square test or Fisher’s
exact test when appropriate.
According to previous studies in the renal transplant population, symptom
occurrence and symptom distress scores were analyzed by means of ridit analysis.12
Ridits represent a probability measure Relative to an Identified Distribution, which
can be analyzed parametrically. The ridit of a (sub)sample is always compared with
the ridit of a chosen reference group and represents the probability that a randomly
selected individual from that (sub)group scores higher on the response variable
than a randomly selected individual of the reference group. The ridit of the reference
group is by definition 0.500. For calculation of symptom distress, those symptoms
that never occurred were converted to missing values, in order to avoid anticipatory
symptom distress.8 In order to determine a rank order of most frequently occurring
and most distressing symptoms at baseline, a ridit was calculated for each item,
using the frequency distribution of all answers on all items at baseline as reference
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group. To calculate the evolution of the overall symptom occurrence and distress
score in both cyclosporine and tacrolimus group, the reference group was
constituted by the frequency distribution of the responses of all patients on all items
at baseline. Student’s t-test was used to compare the ridits obtained.
All patients that were alive and not on renal replacement therapy were followed
for renal function and blood pressure and these parameters were analyzed on
intention-to-treat base. In the patients who died or who started on renal
replacement therapy, the last serum creatinine value obtained before death or renal
replacement therapy was used for the analysis. The metabolic parameters and the
symptom experiences were analyzed in the patients who remained on study
medication during follow-up. A p-value of less than 0.05 (two-sided) was considered
statistically significant.
Results
A total of 124 patients were included in the study, 64 were converted to tacrolimus
and 60 remained on cyclosporine. Mean time after transplantation was 6.6 ± 3.7
years for the tacrolimus group and 5.7 ± 2.7 years for the cyclosporine group. The
demographic data have been described before.9 At baseline, the cyclosporine level
was 129 ± 42 ng/ml in the cyclosporine group and 130 ± 42 ng/ml in the tacrolimus
group. During follow-up, the cyclosporine level remained unchanged in the
cyclosporine group. In the tacrolimus group the tacrolimus level was 7.2 ± 2.0
ng/ml at three months and 6.6 ± 1.8 ng/ml at two years after randomization.
Baseline prednisone dose was equal in both groups (0.10 ± 0.04 mg/kg). Baseline
azathioprine dose was 0.88 ± 0.40 mg/kg (n=10) in the tacrolimus group and 0.95
± 0.47 mg/kg (n=15) in the cyclosporine group. In the cyclosporine group, two
patients used mycophenolate mofetil 2000 mg/day. Prednisone was stopped in two
patients, and they were both withdrawn from the study. Azathioprine was stopped
in one patient in the tacrolimus group and in one patient in the cyclosporine group. 
The study protocol was not completed until the end of follow-up in 17 patients in
the tacrolimus group and in 15 patients of the cyclosporine group (table 1). In the
tacrolimus group two patients reached ESRD, due to biopsy-proven chronic
allograft nephropathy. In the cyclosporine group one patient, known to have
recurrent membranous glomerulonephritis, reached ESRD. In each group, one
patient was withdrawn from the study due to deteriorating renal function associated
with chronic allograft nephropathy (tacrolimus group) and cyclosporine
nephrotoxicity (cyclosporine group), respectively. 
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Renal function
Prior to inclusion, all patients had a stable serum creatinine concentration. During
the two years follow-up period, serum creatinine increased in the cyclosporine group
from 142 ± 48 to 157 ± 62 µmol/l (p<0.001), while it remained stable in the
tacrolimus group (139 ± 32 µmol/l at baseline and 145 ± 56 µmol/l at 24 months,
p=0.26, p<0.05 for comparison between groups, fig. 1). In the cyclosporine group
the endogenous creatinine clearance decreased from 59 ± 26 ml/min to 49 ± 22
ml/min (n=50; p<0.001), whereas renal function remained stable in the tacrolimus
group (60 ± 22 ml/min and 64 ± 33 ml/min, n=58, p<0.01 for comparison between
groups). 
In the cyclosporine group, 30 patients (50%) had a more than 10% rise in serum
creatinine level during the two years of follow-up, as opposed to 15 patients (23.4%)
in the tacrolimus group, while 6 patients (10%) in the cyclosporine group had a
more than 10% improvement in serum creatinine level during follow-up, compared
to 20 patients (31%) in the tacrolimus group (p<0.001).
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Table 1 Patients not completing the study
cyclosporine tacrolimus
Death of patient 6 (10%) 2 (3.1%)
    cardiovascular      3       2
    malignancy         1                          0
    infection         1                          0
    pulmonary embolism      1                          0
End-stage renal disease 1 (1.7%) 2 (3.1%)
Withdrawal of study medication
   deterioration of renal function 1 (1.7%) 1 (1.6%)
   hypertension                                   2 (3.3%) 0 (0%)
   new-onset DM 0 (0%) 2 (3.1%)
   dysregulation of pre-existent DM 0 (0%) 2 (3.1%)
   other side effects 5 (8.3%) 8 (12.5%)
   Total 15 (25.0%) 17 (26.6%)
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Proteinuria did not significantly change in either group during follow-up (median
baseline value 0.2 (0-4.7) g/24 hours in the cyclosporine group and 0.2 (0-3.6)
g/24 hours in the tacrolimus group).
Cardiovascular Risk Factors
In the tacrolimus group the systolic and diastolic blood pressure (manually
measured) were reduced from 144 ± 20 mm Hg to 137 ± 21 mm Hg  (p<0.001),
and from 84 ± 11 mm Hg to 80 ± 9 mm Hg (p<0.01), respectively (fig. 2). As a
result, blood pressure in the tacrolimus group was significantly reduced when
compared to the cyclosporine group (p<0.01). The dynamap blood pressure
readings essentially showed the same results (data not shown).   
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Figure 1 Serum creatinine
(mean and SEM) on cyclosporine
(–––––) and on tacrolimus 
(-----).
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Figure 2 Systolic and diastolic blood pressure (mm Hg, mean and SEM) on cyclosporine (–––––) and
on tacrolimus (-----).  P<0.01 comparing the AUC on cyclosporine and on tacrolimus for both systolic
and diastolic blood pressure.
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In the cyclosporine group the systolic blood pressure was reduced by at least 12
mmHg in 15 patients (25%), as opposed to 28 patients (44%) in the tacrolimus
group (p<0.05). The diastolic blood pressure was reduced by at least 12 mmHg in
5 (8%) cyclosporine treated patients and 17 (27%) tacrolimus treated patients
(p<0.01).
The number of antihypertensive drugs per patient in the cyclosporine group was
1.9 ± 1.0 at baseline and 2.3 ± 1.1 at two years follow-up. In the tacrolimus group
the number of antihypertensive drugs was 2.0 ± 1.1 at baseline and 2.3 ± 1.1 at
two years follow-up (no differences between groups). 
Serum total and LDL cholesterol, and serum triglycerides were significantly
reduced in the tacrolimus group, from 5.9 ± 0.8 mmol/l to 5.2 ± 0.8 mmol/l
(p<0.001), from 3.6 ± 0.8 mmol/l to 3.1 ± 0.8 mmol/l (p<0.001), and from 2.1 ±
1.0 mmol/l to 1.7 ± 1.1 mmol/l (p<0.05), respectively (p<0.001 for comparison
between groups for total and LDL cholesterol and p<0.01 for triglycerides, fig. 3).
Serum HDL cholesterol level remained unchanged in both groups. The use of a
statin did not influence the changes in the serum lipid levels. Commencement of
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statin treatment or an increase in the dosage according to predefined guidelines,
was necessary in three patients of the tacrolimus group and in ten patients of the
cyclosporine group. After conversion to tacrolimus the statin was stopped in one
patient, whereas this did not occur in the cyclosporine group.
The fasting glucose level and the HbA1c level were analyzed for diabetic and non-
diabetic patients separately, since in diabetic patients both glucose and HbA1c levels
are influenced by dietary (non)-compliance and changes in medication. Fasting
glucose and HbA1c levels did not change in either group during follow-up (table
2). In the cyclosporine group three patients developed new-onset diabetes mellitus
versus four patients in the tacrolimus group. In the diabetic patients of the
cyclosporine group (n=8), the antidiabetic treatment remained unchanged in five
patients. In two patients the dosage of antidiabetic medication had to be increased
and one patient was started on insulin. In the diabetic patients of the tacrolimus
group (n=8), the antidiabetic medication remained unchanged in three patients.
In two patients the dosage of antidiabetic medication had to be increased and two
patients were started on insulin. In one patient the dosage of insulin was reduced. 
The Framingham risk score was significantly reduced from 5.7 ± 4.3 at baseline to
4.8 ± 5.3 after two years in the tacrolimus group (p<0.05), and remained unchanged
in the cyclosporine group (6.0 ± 3.1 at baseline and 6.2 ± 3.6 at 24 months, p<0.05
for comparison between groups, fig. 4). The use of a statin at baseline did not
influence the change in Framingham risk score upon conversion to tacrolimus.
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Symptom experience associated with side effects of 
immunosuppressive therapy
In the tacrolimus group eight patients were taken off tacrolimus due to the following
side effects: hair loss (n=2), headache (n=2), diarrhea (n=1), palpitations (n=1),
tremor (n=1) and toxic exanthema (n=1). In the cyclosporine group two patients
were withdrawn from the study due to gingival hyperplasia (n=1) and to severe
osteoporosis for which prednisone was stopped (n=1). In addition, two patients
wanted to be taken off cyclosporine and one patient was converted from cyclosporine
to azathioprine because of her wish to become pregnant.   
The ten most frequently occurring side effects at baseline were in decreasing order
of frequency: increased hair growth, fatigue, bruises, excessive appetite, poor
concentration, changed bodily appearance, poor vision, fragile skin, swollen
ankles, and insomnia. The ten most distressing side effects at baseline were:
impotence for men and painful menstruation for women, fragile skin, insomnia,
warts, poor concentration, back pain, muscle weakness, stomach complaints,
fatigue and nightmares. The item hallucinations was excluded from the analysis of
symptom distress since it occurred in only one patient.
The overall ridit for symptom occurrence evolved significantly after randomization,
both in the cyclosporine and in the tacrolimus group. A significant increase
(p<0.0001) in symptom occurrence was observed in patients on cyclosporine at
3, 12 and 24 months after baseline measurement (fig. 5). Conversely, patients
who were converted to tacrolimus experienced a significant decrease (p<0.0001)
of symptom occurrence compared to baseline level. The ridit of 0.458 for the
tacrolimus group at 12 months means that a randomly selected patient from that
group has a chance of 45.8% to score higher than a randomly selected patient at
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baseline (reference group). This chance of 45.8% is significantly lower than the
chance of 50% (ridit 0.500) inherent to the reference group.
For symptom distress, the overall ridit of the tacrolimus group at 3 months after
conversion was significantly increased (p<0.0001), while the ridit of the cyclosporine
group was decreased. Nonetheless, at 12 and 24 months, patients of the tacrolimus
group reported significantly less, and cyclosporine patients significantly more
symptom distress compared to the baseline level.
Discussion 
This randomized controlled study demonstrates that after conversion from
cyclosporine to tacrolimus in stable renal transplant patients graft function remains
stable as opposed to a gradual deterioration of graft function when continuing on
cyclosporine. Furthermore, replacement of cyclosporine by tacrolimus is followed
by an improvement in cardiovascular risk profile, which is sustained during a two
year follow-up period. In addition, the occurrence of and distress due to side-effects
is reduced.  
In patients using tacrolimus as part of the initial immunosuppressive treatment,
the incidence of acute rejections and of steroid-resistant rejections is reduced,
compared to patients using cyclosporine,6;7 without affecting one year graft and
patient survival. Acute rejection is a major risk factor for developing chronic allograft
nephropathy,13 and several studies have suggested that tacrolimus may indeed
improve long-term graft survival rates. Data from the UCLA-UNOS (United Network
for Organ Sharing) kidney transplant registry showed a graft half-life of
approximately 14 years on tacrolimus and 8 to 9 years on cyclosporine and other
immunosuppressive agents.14 Since this first report several other studies have
provided evidence that compared to an initial immunosuppressive protocol including
cyclosporine, a protocol including tacrolimus may increase graft half-life.7;15 The
influence of tacrolimus on graft survival however is not unequivocal. In the analysis
of Hariharan et al., the use of tacrolimus did not contribute to the recent
improvements in graft survival.16
The putative beneficial effect of tacrolimus on graft function and ultimately also
graft survival, may be related to several favourable effects of tacrolimus compared
to cyclosporine. Chronic allograft nephropathy is the leading cause of late graft
failure and may result from chronic rejection as well as from non-immunologic
processes like calcineurin inhibitor nephrotoxicity and graft vascular disease.17 The
occurrence of an acute rejection is the strongest predictor for the development of
chronic rejection,17 and tacrolimus reduces the incidence of acute rejections.
Secondly, tacrolimus may be less nephrotoxic than cyclosporine, thus contributing
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to the prolonged graft survival. The induction of profibrotic cytokines like 
osteopontin18 and transforming growth factor (TGF)-β19 by cyclosporine is one of
the pathophysiologic mechanisms in chronic cyclosporine nephropathy. Although
TGF-β is also involved in chronic tacrolimus nephropathy,20 several studies
suggested a reduced renal mRNA-expression of TGF-β or other profibrotic genes
on tacrolimus versus cyclosporine.21;22 Finally, hyperlipidemia and hypertension 
are important non-immunologic factors contributing to chronic allograft 
nephropathy.23-25 In this study, we observed reductions in serum LDL cholesterol
and triglyceride levels and blood pressure, that were apparent at three months
after conversion to tacrolimus and persisted until the end of follow-up. This sustained
improvement in serum lipid levels as well as in blood pressure is likely to be of
benefit in maintaining graft function. 
Mayer et al. reported a reduced incidence of CAN after the use of tacrolimus as
part of the initial immunosuppression.7 It is of interest to see that even in our study
population, consisting of patients that were 6.1 ± 3.2 years post-transplantation,
the course of the graft function can still be improved by conversion to tacrolimus.
In this respect, the question can be raised whether equipotent dosages of
tacrolimus and cyclosporine were used. In our population, consisting mainly of
Caucasian patients, the dosage of tacrolimus was sufficient to prevent acute
rejections in all patients. The mean tacrolimus trough level (about 7 ng/ml) as well
as the mean cyclosporine trough level (about 130 ng/ml) were within the ranges
that have been advised for maintenance immunosuppressive therapy after renal
transplantation.26 The tacrolimus levels in our patients were similar to the levels
found in the study of Mayer et al.7 A second question is whether the way of
cyclosporine monitoring could have influenced the results. When this study was
designed, it was common practice to use the trough level (C0) for monitoring.
However, it is now recognized that the area-under-the-curve for the first 4 hrs
postdose (AUC0-4) is superior to the C0 level of cyclosporine in predicting the risk
for acute rejection and cyclosporine-induced nephrotoxicity,27 and the two-hours
postdose (C2) level of cyclosporine is an accurate surrogate marker of the AUC0-
4 cyclosporine level.28 Prospective studies on the longterm effects of replacing C0
monitoring by C2 monitoring in renal transplant patients are limited. Available data
suggest that dose reduction in overexposed patients leads to improvements in renal
function and blood pressure.29 However, it is currently unclear whether C2
monitoring can result in comparable effects on graft function, blood pressure and
serum lipids as we have observed after conversion from cyclosporine to tacrolimus.
We previously already showed that conversion from cyclosporine to tacrolimus
resulted in a reduction in systolic and diastolic blood pressure, and in an
improvement in several metabolic cardiovascular risk factors, including total and
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LDL cholesterol levels, triglyceride levels, fibrinogen levels, and the oxidizability of
the LDL particles.9 We now demonstrate that this improvement in the cardiovascular
risk profile is sustained. Although the reductions in systolic and diastolic blood
pressure are modest, in patients with a high risk of developing cardiovascular
disease, like renal transplant patients, the numbers-needed-to-treat to prevent
cardiovascular disease or cardiovascular death are relatively small. For example,
in case of a reduction of the systolic blood pressure with 12 mmHg, the numbers-
needed-to-treat to prevent cardiovascular disease is only 10.30
During the two years of follow-up, conversion from cyclosporine to tacrolimus did
not affect plasma fasting glucose and HbA1c levels, and there was no significant
difference in the occurrence of new-onset diabetes mellitus. The diabetogenic effect
of tacrolimus is dose-related, and the risk of developing diabetes mellitus is highest
in the initial period after transplantation when high trough levels are reached,31
whereas at standard maintenance trough levels, no difference between cyclosporine
and tacrolimus could be determined with regard to their diabetogenic properties.32
The risk of developing diabetes mellitus after conversion to tacrolimus appears to
be restricted to patients who already experience a disturbed glucose tolerance prior
to therapy.6;33
The improvements in lipid profile and blood pressure after conversion to tacrolimus
resulted in a sustained reduction of the Framingham risk score. This cardiovascular
risk score was developed in a predominantly caucasian population without specific
underlying diseases11 and has been validated in renal transplant patients, where
it was shown to predict ischemic cardiovascular events, though underestimating
the absolute risk, especially related to diabetes mellitus.34 In the general population
the observed reduction in Framingham risk score upon conversion to tacrolimus
would imply a relative reduction of approximately 20% in the estimated risk for
coronary heart disease over a period of 10 years. Although it is likely that renal
transplant patients will also benefit from the reduced cardiovascular risk score, it
is difficult to extrapolate the risk rates to this specific population. 
After conversion from cyclosporine to tacrolimus, the occurrence of symptoms
associated with side-effects of the immunosuppressive regimen decreased
significantly. This was also observed for symptom distress, except for the
measurement at three months after conversion. These findings demonstrate the
beneficial effect of conversion to tacrolimus in terms of patients’ symptom experience.
Patients’ subjective appraisal of symptoms associated with side-effects is very
important for their quality-of-life,35 and is also of great importance for the motivation
to comply with the medication regimen.36 Several studies have demonstrated a
relation between distressing symptoms and subsequent non-compliance with
immunosuppressive medication.37;38 Further analysis of symptom occurrence and
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symptom distress at item level will provide a more detailed picture of the evolution
of individual symptoms after conversion from cyclosporine to tacrolimus.
In summary, conversion from cyclosporine to tacrolimus in stable chronic renal
transplant patients has a beneficial effect on renal graft function, results in a
sustained improvement in the cardiovascular risk profile and reduces the fequency
and distress of side-effects. In our opinion, for most renal transplant patients
tacrolimus will be the drug of choice when long-term treatment with a calcineurin
inhibitor is indicated.
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Abstract
Background.  Recurrence of focal segmental glomerulosclerosis (FSGS) is
characterized by the early onset of severe proteinuria after renal transplantation.
Prognosis of recurrent FSGS can be improved by early start of plasmapheresis
treatment. Thus, it is important to differentiate proteinuria due to recurrence from
proteinuria due to preservation injury. There are no data on the time-course of
proteinuria after living-donor (LD) transplantation.
Methods. In ten patients receiving a kidney graft from a LD, the excretion of high
(HMW; albumin, transferrin and immunoglobulin G) and low molecular weight
proteins (LMW; β2-microglobulin and α1-microglobulin) was measured at various
time-points during the first five days after transplantation.
Results.  Immediately after restoration of the circulation we observed a massive
non-selective HMW proteinuria, indicative of glomerular damage. This proteinuria
rapidly decreased to slightly elevated values beyond 24 hrs after transplantation.
LMW proteinuria, reflecting tubular damage, was also prominent, and remained
grossly abnormal even at day five. 
Conclusion. Massive proteinuria within 24 hours after LD transplantation must not
be mistaken for recurrence of FSGS, thereafter proteinuria rarely exceeds 1 g/day. 
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Introduction
After renal transplantation recurrence of focal segmental glomerulosclerosis
(FSGS) occurs in about 30% of cases,1;2 often within days after transplantation.1
The early stage of recurrence is characterized by the sudden onset of severe
proteinuria, initially without impaired graft function and without histological
changes on renal biopsy.2 The proteinuria is attributed to an unidentified circulating
plasma factor, probably a protein bound to an immunoglobulin, or a fragment of
an immunoglobulin.3 Prognosis of untreated recurrence of FSGS is poor, leading
to graft loss in 40-50% of cases2 and early recurrence of FSGS, within the first two
days after transplantation, has the worst prognosis.4 Plasma exchange is effective
in reducing proteinuria due to recurrence, if instituted soon after the initial
presentation of proteinuria.5;6 For this reason early diagnosis and institution of
plasma exchange is important. Since recurrence of FSGS can occur very soon after
transplantation, one has to differentiate the observed proteinuria from the
proteinuria that may be the result of preservation-reperfusion damage. Even with
the improved preservation techniques, which have enabled allocation and
transportation of the kidney, injury does occur, which is caused by hypothermia,
ischemia and/or the generation of free radicals during reperfusion. The severity of
this injury is proportional to the length of the ischemia-time.7;8 Tubular epithelial
cells as well as glomerular visceral epithelial cells are damaged, the latter being
responsible for proteinuria.7;8 Glomerular proteinuria following renal transplantation
has also been attributed to the loss of heparan sulfate proteoglycan from the
damaged glomerular basement membrane.9 After cadaveric kidney donation a
severe nonselective glomerular and tubular proteinuria was seen.9 This glomerular
proteinuria persisted for 48 hours, with a gradual improvement thereafter. Only
after 10 days, glomerular proteinuria was abolished in most of the patients.9 There
are no data on the time-course of proteinuria after living-donor kidney
transplantation. 
In this observational study, timed urine samples were taken from the ureteral splint
in renal transplant patients receiving a kidney from a living donor (LD), within
minutes after releasing the vascular clamps, and two, four and six hours, and one,
two, three and five days thereafter. According to local protocol, the ureteral splint
was removed at five days after transplantation. Urine was solely taken directly from
the ureteral splint to avoid admixture with urine from the native kidneys. In the
urine samples albumin, transferrin and immunoglobulin G (IgG) were determined
as markers of glomerular proteinuria, and the LMW proteins α1-microglobulin and
β2-microglobulin were determined as markers of tubular proteinuria. Blood
samples were collected daily for determination of creatinine, total protein content,
albumin, transferrin, IgG and β2-microglobulin. Details of the various assays have
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been described before (10). Urinary protein concentrations were corrected for blood
contamination when the urinary hemoglobin concentration exceeded 10 µmol/l,
since in these cases a significant error could occur. This correction was needed in
10% of the urine samples. Urinary excretion rates could not be calculated from the
urine samples that were collected from the ureteral splint, since in several patients
overflow of urine to the urinary bladder occurred. To correct for these errors, urinary
excretion was estimated from the urinary protein/creatinine ratios corrected for
the time-averaged urinary creatinine excretion. The fractional excretion of protein
was expressed as percentage of the creatinine clearance. The protein selectivity
index was calculated as the clearance of IgG divided by the clearance of transferrin.
Results are given as median and range. 
Ten patients (7m/3f) were included in this study, median age at transplantation 45
(21-66) years. None of the patients had FSGS as underlying disease. In six cases
the donor was a first-degree relative and in four cases the spouse. There were six
male and four female donors, aged 48 (20-64) years. Nephrectomy was performed
by laparotomy in nine cases and by laparoscopy in one case. Immediately following
nephrectomy the renal artery was cannulated and perfused with preservation fluid
at a temperature of 4 °C, followed by storage on ice. Preservation fluid used was
Eurocollins (n=5, Fresenius, Oberursel, Germany), and University of Wisconsin-
solution (n=5, UW-solution, viaspanTM, DuPont Pharma GmbH, Bad Homburg,
Germany). First warm ischemia time was 1 (1-7) min, anastomosis time was 32
(27-46) min and total ischemia time was 105 (53–198) min. Immunosuppression
consisted of prednisone, tacrolimus and mycophenolate mofetil. One patient also
received daclizumab (1 mg/kg) at transplantation. Blood pressure was targeted
below 140/90 mm Hg. No patient received an angiotensin-converting enzyme
inhibitor nor an angiotensin II (AT1)-receptor antagonist. Informed consent was
obtained from all patients. 
After transplantation renal allograft function rapidly improved in all patients except
one (Table 1). In this last patient without apparent complications during or after
the operation, the endogenous creatinine clearance ranged from 11 to 23 ml/min
during the first four postoperative days and gradually increased thereafter. 
Immediately after transplantation gross albuminuria of 10.4 mg/min (range
0.55–159.5 mg/min) was observed. Although albuminuria rapidly decreased,
persistent macro-albuminuria (> 200 µg/min) was still present in six patients at
24 hours after transplantation. Even at five days after transplantation albuminuria
was normal (< 20 µg/min) in only one patient (Table 1). Urinary transferrin and
IgG excretion paralleled albuminuria (Table 1). At onset, proteinuria was non-
selective in nine patients, with a median selectivity index of 0.47 (0.15-0.99). The
selectivity index did not change during the study period. In the first urine sample
also a massive LMW proteinuria was evident, with urinary excretion rates up to
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100-500 fold of normal (Table 1). LMW proteinuria only gradually decreased, and
values were still highly abnormal in all patients even at five days after
transplantation. The difference in the time course of glomerular and tubular
proteinuria is depicted in figure 1, clearly showing a slower improvement of fractional
excretion of β2-microglobulin, a marker of tubular dysfunction, as compared to the
fractional excretion of albumin. In this small group of patients we did not observe
a relation between the level of post-transplant proteinuria and ischemia time or
the type of preservation solution. However, these data are biased, since ischemia
time in patients receiving a kidney preserved with UW solution was longer than
after using Eurocollins as preservation fluid (164 min, range 135-198 min, versus
58 min, range 53-74 min, p<0.01, Mann Whitney U test).
Our data illustrate that even with the improved preservation techniques and with
the short ischemia times after living-donation, allograft injury does occur with
evidence of tubular and glomerular dysfunction. In our study glomerular proteinuria
was approximately 10 times lower than the proteinuria that has been observed
after cadaveric kidney donation, which probably is related to the differences in cold
ischemia time.9 In contrast, the excretion of LMW proteins in our study was very
high and comparable to the excretion-rates found after cadaveric kidney donation,9
compatible with an increased sensitivity of tubular cells to cold ischemia. We also
noted that glomerular permeability improved more rapidly than tubular dysfunction.
Although this also is compatible with an intrinsic difference in sensitivity of
glomerular and tubular cells for ischemia or differences in recovery potential, we
62
Chapter 4
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 2 4 6 24 48 72 120
time posttransplantation (hrs)
5
10
15
20
25
30
35
40
45
50
ß2m
alb
FE alb (%) FE ß2m (%)
Figure 1 Time-course of fractional excretion of albumin (FE alb, median value)
and b2-microglobulin (FE b2m) after living-donor kidney transplantation
bw.van leeuwen  12-07-2005  10:34  Pagina 62
cannot exclude that the use of tacrolimus may have contributed to this slower
recovery of tubular cells. For daily practice, our data indicate that it will not be easy
to diagnose recurrent FSGS within the first 24 hours after LD transplantation.
Thereafter however, proteinuria should be less than 1 g/day and higher rates of
protein excretion should lead to suspicion.
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Abstract
Background The reported outcome of renal transplantation in patients with the
hemolytic uremic syndrome (HUS) varies greatly, probably related to the diverse
etiology of HUS. In this single-center retrospective study, we have analyzed the
recurrence-rate, the incidence of acute rejections, and graft survival in patients
suffering from adult-onset and childhood-onset HUS. 
Methods The medical records of 35 patients with ESRD due to HUS, who received
50 renal allografts, were reviewed. A definite recurrence of HUS was diagnosed if
both clinical and histological signs of thrombotic microangiopathy (TMA) were
present in the absence of any endovasculitis. If there were signs of mild
endovasculitis, a probable recurrence was diagnosed. 
Results After first renal transplantation no definite and one (6%) probable
recurrence occurred in 18 patients with childhood-onset HUS, as opposed to seven
(41%) definite and three (18%) probable recurrences in 17 adult-onset HUS
patients (O.R. 13.4, 95% C.I. 1.7–105.7). In the latter patients early use of
cyclosporine increased the risk for recurrence. The incidence of acute rejections
was increased compared to matched controls (O.R. 1.52, 95% C.I. 1.05–2.19 for
adult-onset and O.R. 1.88, 95% C.I. 1.34-2.62 for childhood-onset HUS). One-
year graft survival in adult-onset HUS was poor (29%), whereas one-year graft
survival in childhood-onset HUS was comparable to matched controls. 
Conclusions In adult-onset HUS the recurrence-rate and the incidence of acute
rejections are high, resulting in a detrimental graft survival. In childhood-onset
HUS the recurrence-rate is low, but the post-transplantation course is complicated
by an increased incidence of acute rejections. 
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Introduction
The hemolytic-uremic syndrome (HUS) is characterized by microangiopathic
hemolytic anemia, thrombocytopenia and acute renal insufficiency. The etiology of
HUS is quite diverse. The classical or diarrhea(D+)-associated form of HUS, caused
by a verocytotoxin-producing Escherichia Coli, is predominantly seen in children.
In these patients acute renal failure with signs of thrombotic microangiopathy (TMA)
follows a period of bloody diarrhea. In the majority of cases renal function improves,
however in some patients recovery is incomplete and ultimately about 5-15% of
patients develop end-stage renal failure.1;2 The atypical or nondiarrhea (D-)-
associated form of HUS is most frequently seen in adults. Triggering factors in D-
HUS include pregnancy or the use of estrogen-containing oral contraceptives,
bacterial or viral infections, malignancies, and a wide range of drugs. Some cases
of D-HUS are familial. Nonetheless, most cases of D-HUS are idiopathic. Although
some patients with D-HUS experience a relapsing course of the disease, many
patients present with acute, irreversible renal failure.3-5
Renal transplantation is the preferred treatment option for patients with ESRD. In
patients with HUS, the post-transplant course may be complicated by a recurrence
of the original disease. Several small-sized studies have reported the outcome 
of renal transplantation in patients with HUS. The data on recurrence-rate, risk 
factors, and graft-survival vary widely, probably related to differences in study 
populations.6-13 The differences in reported recurrence-rates might also be caused
by difficulties in establishing a definite diagnosis of recurrent HUS. Acute vascular
rejection (AVR) may mimic a recurrence of HUS, both clinically and histologically.
Furthermore, calcineurin inhibitors and malignant hypertension may cause TMA. 
In this retrospective single-center study, we have analyzed our data regarding 35
HUS-patients, with respect to recurrence of HUS, the occurrence of acute rejections,
and graft survival. 
Materials and methods 
The medical records of all patients suffering from end-stage renal failure due to
HUS, who received a kidney transplant in the University Medical Center of Nijmegen
were reviewed. The criteria for the primary diagnosis of HUS were: signs of
microangiopathic hemolytic anemia (decreasing hemoglobin level, fragmentocytes
and raised LDH), thrombocytopenia (<100 x 109/l), and acute renal failure. Since
the etiology of HUS differs, with D+HUS accounting for at least 80% of childhood-
cases and no more than 5% of adult cases,14 we have divided patients in two groups
according to age at onset of HUS, <16 and >= 16 years, respectively. 
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We have evaluated the post-transplant course for development of HUS. A definite
recurrence of HUS was defined by the presence of both clinical and histological
criteria. Clinical signs of HUS were thrombocytopenia (<100 *109/l) and signs of
microangiopathic hemolytic anemia with decreasing hemoglobin and fragmentocytes.
Histological criteria for recurrence of HUS were: the presence of glomerular thrombi,
often accompanied by swelling of endothelial cells or detachment of endothelial cells
from the glomerular basement wall, ischemic changes of the glomeruli, and
intravascular thrombi in arteries and arterioles, often accompanied by intimal edema,
fibrinoid degeneration and myointimal cell proliferation of the vessel wall. These signs
of TMA however can also be seen in patients with AVR. The only lesion considered
to be specific for AVR is endovasculitis, due to infiltration of inflammatory cells from
the intima towards the outer layers of the vessel wall. Therefore, if signs of TMA
were present without signs of endovasculitis, the renal biopsy was considered
compatible with a definite recurrence of HUS. If there was a severe TMA with
disproportionately mild signs of endovasculitis, we considered the renal biopsy
consistent with a probable recurrence of HUS. Since the differentiation between
recurrence of  HUS and AVR can be difficult, we also evaluated the rate of acute
rejections. Acute rejection was defined by a rise in serum creatinine by more than
20% not explained by other causes, for which a course of antirejection treatment
was given. Renal biopsy was performed in patients with a severe or steroid-resistant
rejection. All renal graft biopsies were revised by a pathologist who was blinded for
the clinical data and the initial histological diagnosis. Each episode of deteriorating
graft function was attributed to a single cause, the most likely, based on clinical
and/or histological grounds.
The incidence of acute rejections after first renal transplantation in HUS-patients was
compared to controls not suffering from HUS who had received their first renal
transplant, matched for HLA-matching, anti-HLA-antibodies, immunosuppression, and
age. For each HUS-patient there were 2 matched controls. Finally, in all transplant-
biopsies from HUS-patients with either HUS or AVR where biopsy-material was still
available, immuno-histochemical staining for C4d was performed using a mouse
monoclonal antibody (Biogenesis Inc., Ede, the Netherlands), and compared with
transplant biopsies of 14 control-patients not suffering from HUS, with AVR, either
with or without TMA. These controls were all treated with prednisone and azathioprine
to avoid confusion with cyclosporine-induced TMA. 
From 1974 to 1983, basic immunosuppression in our center consisted of azathioprine
and prednisone. Thereafter we have used calcineurin inhibitor based treatment
regimens. In patients with childhood-onset HUS the prevailing regimen was always
used. In contrast, in patients with adult-onset HUS we have for a long time been
reluctant to use a calcineurin inhibitor as initial therapy, and lately these patients
have received a combination of daclizumab, mycophenolate mofetil, and prednisone. 
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Statistical Analysis
Values are given as mean ± standard deviation in case of normal distribution or
otherwise as median and range. Statistical analysis was performed using the
Statistical Product and Services Solutions (SPSS) package, version 9.0 (Chicago,
Illinois, USA). 
Continuous values were analyzed using Student’s t-test or Mann Whitney U test
when appropriate. Categorical values were analyzed using the chi-square test or
Fisher’s exact test when appropriate. Univariate survival analysis was performed
using Kaplan Meier-analysis with log-rank test and for multivariate analysis Cox’s
proportional hazard model using forward selection was used. Analysis of the
incidence of acute rejections and AVR was censored for graft and patient failure
and recurrence of HUS. A p-value of less than 0.05 was considered statistically
significant.
Results
Study population
Between March 1974 and January 2001 35 patients with end-stage renal disease
due to HUS have received a total of 50 kidney transplants in the University Medical
Center in Nijmegen. In those years a total of 2310 renal transplants have been
performed in this center.  Patients’ characteristics are described in table 1.
Seventeen patients with adult-onset HUS received 25 renal transplants: 11
patients were transplanted once, five patients twice, and one patient four times.  
Eighteen patients with childhood-onset HUS received a total of 25 renal transplants:
13 patients were transplanted once, three patients twice and two patients three
times. In seven patients with childhood-onset HUS no cause of HUS was specifically
mentioned. However, these patients were referred from other hospitals long after
the initial presentation of HUS in order to start with renal replacement therapy. It
is most likely that in these patients HUS was also diarrhea-associated. 
First renal transplantation in patients with adult-onset HUS
Thirteen patients received a kidney from a postmortal donor and four from a living-
related donor, including one from an HLA-identical twin-brother. Median age at
transplantation was 36 (18 – 62) years, median time on hemodialysis was 19 (8
– 37) months. In two patients bilateral nephrectomy was performed prior to renal
transplantation, because of refractory hypertension. Initial immunosuppression
consisted of prednisone and azathioprine in 12 patients. Four out of these 12 patients
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later received cyclosporine because of severe rejections (n=2) or side effects due
to azathioprine (n=2). Two patients received prednisone and cyclosporine as initial
immunosuppression, one received prednisone, cyclosporine and MMF, and two
patients received prednisone, MMF and daclizumab. One of these last two patients
later was converted to tacrolimus because of severe acute rejections.
Seven (41%) patients developed a definite recurrence of HUS. All seven recurrences
were histologically confirmed either by transplant biopsy (n=4) or after transplant
nephrectomy (n=3). Three (18%) patients had a probable recurrence of HUS. In
these last three patients there were clear signs of TMA, both clinically and
histologically, but there were also mild signs of endovasculitis, though
disproportionate to the severe signs of TMA.
Recurrence developed after a median time of 30 days, range 4 days to 16.6 years
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Table 1 Clinical characteristics of patients with childhood-onset HUS and adult-onset HUS
childhood-HUS
n=18
adult-onset HUS
n=17
sex (male/female) 11/7 3/14
age at diagnosis (yrs) 3 (1-13) 33 (17-62)
renal biopsy at presentation 5 (28%) 9 (53%)
etiology
diarrhea-associated 5 (28%) 1 (6%)
non-diarrhea-associated 6 (33%) 16 (94%)
      familial 1 2
      postpartum 0 1
      idiopathic 5 13
unknown 7 (39%) 0 (0%)
development of ESRD
acute irreversible ESRD 3 (17%) 16 (94%)
gradually deteriorating renal function 12 (67%) 1 (6%)
relapsing course 3 (17%) 0 (0%)
interval between diagnosis HUS and ESRD 86 months
(3 days – 30 yrs)
2 days
(0 days – 51 months)
Values represent number (percentage) of patients or median (range).
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(fig. 1). In all patients with a recurrence transplant function was lost after a median
time of eight days, range zero days to 29 weeks. Exclusion of patients with a
probable recurrence did not alter the results. The seven patients who did not develop
signs of recurrence of HUS were followed for a median time of 68 weeks, range 23
weeks to eight years. 
By univariate analysis the use of cyclosporine starting directly after renal
transplantation was associated with an increased risk for recurrence (p=0.0028).
Gender, time on hemodialysis, acute tubular necrosis (anuria lasting for more than
24 hours, or the need for renal replacement therapy excluding a single treatment
for hyperkalemia), ischemia time, nephrectomy of native kidneys prior to
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20 Figure 1 Incidence of recurrence of
HUS (both definite and probable) in
patients with adult-onset (–––––) and
childhood-onset HUS (-----) after
first renal transplantation. The differ-
ence is significant (p<0.01, Odds
ratio 13.4, 95% C.I. 1.7 – 105.7).
Table 2 Results of Cox proportional hazards analysis of risk factors for recurrence.
Odds Ratio 95% C.I. of Odds ratio p-value
cyclosporine initially 7.3 1.6 – 33.3 0.011
cyclosporine later 0.2 0.0 – 1.4 0.101
gender 2.1 0.4 – 10.8 0.383
time on hemodialysis 2.3 0.4 – 12.0 0.321
acute tubular necrosis 0.9 0.2 – 4.6 0.936
cold ischemia time 3.2 0.4 – 28.9 0.300
nephrectomy 1.1 0.1 – 9.2 0.929
type of kidney donation 3.5 0.4 – 28.3 0.237
ATG 0.4 0.1 – 1.6 0.221
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Figure 2 Incidence of first acute rejec-
tion after first renal transplantation in
patients with adult-onset HUS (–––––)
and their matched controls (......), and
childhood-onset HUS (––––) and
matched controls (-----); p<0.05,
adult-onset vs controls; p<0.001, child-
hood-onset vs controls.
Figure 3 Incidence of acute vascular
rejection after first renal transplanta-
tion in patients with adult-onset HUS 
(–––––) and their matched controls 
(......), and childhood-onset HUS (––––)
and matched controls (-----); p<0.05,
adult-onset vs controls; p=0.12, child-
hood-onset vs controls.  
Figure 4 Graft survival after first renal
transplantation in patients with adult-
onset HUS (–––––), their matched con-
trols (......), and childhood-onset HUS 
(––––) and matched controls (-----);
p<0.05, adult-onset vs controls.
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transplantation, type of kidney donation, and the use of ATG did not significantly
influence the rate of recurrence. Multivariate analysis using the Cox proportional
hazard model confirmed that the only factor associated with a higher rate of
recurrence was the use of cyclosporine immediately after transplantation (relative
risk for patients on cyclosporine 7.3 (95% C.I. 1.6 – 33.3, p=0.01, table 2). A total
of eight patients received a calcineurin inhibitor, three directly after transplantation,
five later on. Seven of these patients received cyclosporine, one patient received
tacrolimus. All three patients who were started on cyclosporine directly after
transplantation developed a definite recurrence of HUS quite early, after four, 10
and 27 days respectively. In the first patient, no cyclosporine trough level was yet
determined, in the second patient cyclosporine trough level was 144 ng/ml and in
the third patient cyclosporine trough levels ranged between 38 and 152 ng/ml. The
remaining five patients received a calcineurin inhibitor on day 22, 28, 55, 127 and
128 days post-transplantation. Only the patient who started cyclosporine after 22
days developed a recurrence of HUS, however this recurrence occurred five months
after cyclosporine had again been withdrawn because of hypertension. The other
four patients have been treated with either cyclosporine (n=3) or tacrolimus (n=1)
for 15 days (stopped because of severe infections), 12 months, 66 months and 89
months without signs of recurrence of HUS. 
The Odds ratio for developing an acute rejection in patients with adult-onset HUS,
compared to matched controls, was 1.52 (95% C.I. 1.05 - 2.19, p<0.05, fig 2). In
5 patients a recurrence of HUS was preceded by a rejection, with a median time
between rejection and recurrence of 5 weeks, range 3 weeks to 15.5 years. Sixty
percent of acute rejections in adult-onset HUS patients were histologically
confirmed, compared to 49% of the acute rejections in the controls. The Odds ratio
for developing an AVR in patients with adult-onset HUS, compared to matched
controls, was 1.81 (95% C.I. 1.05 –3.10, p<0.05, fig 3). Since HUS-patients and
controls were matched for immunosuppressive therapy, mainly consisting of
azathioprine and prednisone, they differed with respect to year of transplantation.
Median year of transplantation was 1989 for HUS-patients and 1984 for controls.
To exclude any bias we have compared the incidence of rejections in 7 HUS-patients
and 24 controls transplanted in the same decade (between 1980 and 1990). Within
two months after transplantation a rejection occurred in all HUS-patients at risk,
as compared to 16 controls (66%). 
Overall one-year graft survival in patients with adult-onset HUS was poor compared
to graft-survival in the control patients, 29% versus 76% (p<0.05; fig 4).
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First kidney transplantation in patients with childhood-onset HUS
Sixteen patients received a kidney from a postmortal donor, two kidneys were from
a living-related donor. Median age at transplantation was 13 (3–48) years and median
time on hemodialysis was 11 (0–59) months. In eight patients bilateral nephrectomy
was performed prior to renal transplantation because of refractory hypertension. Initial
immunosuppressive therapy consisted of prednisone and azathioprine in six patients,
prednisone and cyclosporine in eight patients, prednisone, cyclosporine and
azathioprine in one patient and prednisone, cyclosporine and MMF in three patients.
Two patients who were initially on prednisone and azathioprine later received
cyclosporine because of recurrent rejections.
In these 18 patients with childhood-onset HUS no definite recurrence developed after
renal transplantation. In one (6%) patient a recurrence of HUS was considered
probable (fig.1). This patient had clear signs of TMA at 24 weeks after transplantation,
both clinically and histologically. However, renal biopsy also showed mild signs of
endovasculitis, though disproportionate to the severity of the TMA. This patient had
an unknown type of HUS. His immunosuppression consisted of prednisone and
azathioprine. The remaining patients who did not develop signs of recurrence of HUS
were followed for a median time of 4.0 years (range 1 week – 23 years).
The Odds ratio for developing an acute rejection in patients with childhood-onset
HUS compared to controls was 1.88 (95% C.I. 1.34 – 2.62, p<0.001, fig 2). An
identical percentage of acute rejections was biopsy-proven in the patients suffering
from childhood-onset HUS and their matched controls (50%). The Odds ratio for
developing an AVR was 1.64 (95% C.I. 0.85 – 3.17, p=0.12, fig 3). Of note, HUS-
patients and controls were comparable with respect to year of transplantation
(median 1991). 
One-year-graft survival in childhood-onset HUS was 78%. Graft survival was not
different from matched controls (p=0.78; fig. 4).
Second transplantations 
In six patients with adult-onset HUS a second renal transplantation was performed.
Four patients had lost their previous graft because of a definite (n=3) or probable
(n=1) recurrence. From these four patients two patients developed a clinically and
histologically proven recurrence of HUS after six and 10 days with immediate graft
failure, and one patient developed a probable recurrence after seven days. In one
patient no recurrence of HUS was observed, however, this patient lost her graft at
17 days after transplantation because of a renal artery thrombosis. From the two
patients who lost their first kidney from other causes than recurrence of HUS, one
developed an AVR with TMA after seven days and reached end-stage renal failure
three days later. In view of the extensive endovasculitis we do not consider this a
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recurrence of HUS. One-year graft survival after second transplantation was 17%.
One patient received a total of four renal transplants. She lost her first kidney after
40 days due to a probable recurrence, her second kidney after 17 days due to a
renal artery thrombosis, her third kidney due to a probable recurrence after 19
days and her fourth kidney due to severe rejections after eight weeks. 
In five patients with childhood-onset HUS a second renal transplantation and in
two patients a third renal transplantation was performed, without any recurrence
of HUS. The patient with childhood-onset HUS who developed a probable recurrence
of HUS so far did not receive a second kidney graft.
Treatment of recurrence of HUS
We have not systematically treated patients with adult-onset HUS and a recurrence.
Despite plasma-infusion (n=1) or plasmapheresis (n=1), high-dose prednisone
(n=6), and withdrawal of cyclosporine, graft failure was 100%. Ultimately
transplantectomy was performed in 12 out of 15 cases, concerning both first and
later renal transplantations. 
C4d-immunostaining
In five patients with a definite recurrence of HUS on both clinical grounds as well
as on histologic evaluation of the graft biopsy, with no signs of endovasculitis, the
C4d-immunostaining was negative. In one HUS-patient with severe TMA and mild
endovasculitis, classified as probable recurrence, C4d was positive. In one HUS-
patient with a biopsy-proven AVR, C4d was positive. In 14 controls not suffering
from HUS, C4d was positive in 4 out of 8 cases with AVR and in 4 out of 6 cases
with AVR and TMA. 
Discussion
Our data clearly illustrate the grim outcome of renal transplantation in patients
with adult-onset HUS, with an overall one-year graft survival of less than 30%. In
contrast, graft survival approximated 80% in patients with childhood-onset HUS.
Literature data on the outcome of renal transplantation in patients with HUS are
scarce.15 Analysis of the United Network for Organ Sharing (UNOS) data revealed
1 and 3 year graft survival rates of 82% and 68% respectively, suggesting an only
moderately increased risk of graft failure.16 In the review by Chadban overall
recurrence-rate is estimated at 28%.17 However, these studies are biased because
data of patients with childhood-onset HUS and adult-onset HUS have been
combined.
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It is well established that the outcome of renal transplantation is good in patients
with childhood-onset, diarrhea-associated HUS, with recurrence-rates ranging from
0–10%.6;13 Notably, prognosis is less favourable in children with atypical HUS, with
recurrences occurring in over 50% of patients and graft failure developing in all of
them.9
Literature data on the outcome of renal transplantation in patients with adult-onset
HUS are limited to case reports and small-sized multicenter studies, reviewed by
Lahlou et al.11 The aggregate data support the conclusion of our single center study
that renal transplantation has a dismal prognosis in patients with adult-onset HUS.
Recurrence-rate ranged from 50-60%, with graft failure occurring in more than
90% of patients suffering from recurrence.8;9;11 In most studies recurrences
occurred early after transplantation, in the majority of patients within one month.
In the study of Lahlou recurrences occurred rather late, after 4 months in 6 out of
10 patients, for reasons unknown.
The difference in outcome between patients with childhood-onset HUS and patients
with adult-onset HUS most likely reflects the differences in etiology. Childhood-
onset HUS is mainly caused by an exogenous factor, whereas the development of
adult-onset HUS is more likely related to intrinsic factors that attenuate the
production of prostaglandin I218 or related to a diminished activity of factor H, an
inhibitor of complement activation.19-21
Reported risk factors for recurrence of HUS after transplantation include older age
at onset of HUS10 and a rapid course toward the development of ESRD,10 both
reflecting the difference in outcome between childhood-onset HUS and adult-onset
HUS. Literature data on the favourable effect of bilateral nephrectomy are likely biased
since nephrectomy is performed more often in children. Still, even in adults
recurrence-rate was lower in nephrectomized patients (3/10 vs 16/23).11 Our data
are inconclusive in this respect, with only two adult patients being nephrectomized. 
We observed a higher incidence of recurrence in the few patients that had been treated
with cyclosporine immediately after transplantation. In the patients that were started
on a calcineurin inhibitor later on no recurrence of HUS occurred and also in childhood-
onset HUS the use of cyclosporine was not associated with an increased risk for
recurrence. Some but not all studies have come to similar conclusions.8;10-13 It may
not be surprising that cyclosporine predisposed to recurrent HUS, since calcineurin
inhibitors have been associated with de novo TMA after renal transplantation, probably
related to vasoconstriction, endothelial toxicity and prothrombotic and antifibrinolytic
actions.22;23 The importance of the interval between transplantation and the
introduction of cyclosporine could be related to the ischemia-reperfusion injury or
activation of the coagulation system that occurs immediately after surgery.24 Also,
the high dosage of cyclosporine immediately after transplantation may play a role
although in our patients cyclosporine levels were not high.
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If endothelial injury predisposes to the recurrence of HUS, one could imagine that
ischemia may play an important role. Accordingly, Candinas found an increased
risk for HUS upon non-heart-beating kidney donation.25 However, we have found
no evidence that a prolonged ischemia time increases the risk of recurrent disease.
Some authors have suggested that recipients of a living-related donor graft are at
increased risk for recurrence of HUS, although the evidence is not totally
convincing.10
We have not systematically treated patients with recurrent HUS, although
incidentally patients received plasma infusion or plasmapheresis, or high-dose
prednisone. In most cases the calcineurin inhibitor was withdrawn. In most studies,
plasmapheresis has not been effective in maintaining renal function.8;9 The
efficacy of antihypertensive treatment or the use of antiplatelet drugs such as aspirin
or dipyridamole is also unproven. 
Could our results be biased by incorrect interpretation of clinical or histological data?
Theoretically, it is possible that vascular rejections might be wrongfully diagnosed
as a recurrence. However, we observed more rejections in the patients with HUS
as original renal disease. Even when only looking at biopsy-proven rejections, we
noted more vascular rejections in the patients with HUS. One could hypothesize
that in some patients with HUS who do not develop a recurrence, subclinical injury
to the endothelial cells might occur that predisposes to the development of a
rejection. An increased incidence of acute rejections in patients suffering from
thrombophilic disorders has been reported.26 Alternatively, a rejection process that
damages the endothelial cells might culminate in TMA in patients predisposed to
develop HUS. Interestingly, Miller has observed an increased incidence of glomerular
and intravascular thrombi in HUS-patients suffering from acute rejection, compared
to controls.9 To our knowledge, there are no studies reporting an increased incidence
of acute rejections in HUS-patients, however, an increased incidence of graft loss
due to chronic allograft nephropathy in HUS-patients without a recurrence has been
reported.7;9
The pathophysiological mechanisms for AVR and for HUS differ. HUS is the result
of a primary noninflammatory toxic injury to the endothelium with secondary local
intravascular coagulation, formation of fibrin and activation of platelets. In AVR the
immune system is activated, leading to an inflammatory response. The classical
complement pathway is activated, resulting in the production of C4d and antibodies
against donor endothelium. Recent studies have suggested that vascular rejection
may be identified by the presence of C4d deposition in the peritubular
capillaries.27;28 In accordance with these differential pathophysiological
mechanisms for HUS and AVR, we observed no immunostaining for C4d in our five
HUS-patients with a definite recurrence, as opposed to positive immunostaining in
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8 out of 14 controls with documented AVR. These results are in accordance with
the findings of Nadasdy et al.29
In conclusion, recurrence rate was high and graft survival poor in patients with
adult-onset HUS. Use of cyclosporine as part of the initial immunosuppressive
therapy increased the risk of recurrence. 
Thus far no effective treatment modalities are available. Although the  evidence in
favour of pre-emptive and prolonged plasmapheresis or pretransplant nephrectomy
is limited, we feel that these topics should be subject of further study in view of
the bad outcome in patients with HUS. Probably the most important step would be
to establish a registry for patients with HUS  in which very detailed information of
patient and transplant characteristics would be collected.
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Abstract
Aim: Pauci-immune small vessel vasculitis (SVV) and anti-glomerular basement
membrane (GBM) disease are the most common causes of rapidly progressive
glomerulonephritis (RPGN) and frequently lead to end stage renal disease. For renal
replacement therapy, renal transplantation is the preferred treatment option.
However in patients with glomerular diseases, the outcome of renal transplantation
can be adversely affected by recurrence of the original disease. The information in
the medical literature on the outcome of renal transplantation in patients with RPGN
is limited, because most data are derived from case studies and from studies
involving a small number of patients.
Methods: We have studied the outcome of renal transplantation in patients with
pauci-immune SVV or anti-GBM disease, transplanted in our center between 1968
and 2000. Patient and graft survival were compared with a matched control group
from our hospital. We specifically looked for any evidence of recurrent disease. 
Results: Included in the study were 43 patients (31 male, 12 female) with a mean
age (±SD) of 48 ± 15 years at transplantation. Patients were diagnosed as
Wegener’s granulomatosis (n=8), microscopic polyangiitis (n=7), renal limited
vasculitis (n=18) and anti-GBM disease (n=10). The average follow up was 62 ±
57 months. No graft was lost due to recurrence of the underlying disease. One
patient with Wegener’s granulomatosis had a relapse with only extrarenal
manifestations 5 months after transplantation. Patient and graft survival at 5 years
after transplantation were 77% and 60%. Survival rates were not significantly
different from a matched control group of renal transplant patients with other
underlying diseases, 79% and 56% respectively. Patients with pauci-immune SVV
or anti-GBM disease developed significantly more malignancies than the control
group (Odds ratio 2.82, 95% C.I. 1.18-6.71, p=0.02).  
Conclusions: Recurrence of pauci-immune SVV and anti-GBM disease after
transplantation is rare. Renal transplantation can be successfully performed in
patients with pauci-immune vasculitis or anti-GBM disease. Physicians should be
aware of the greater risk of developing malignancies, especially skin cancer. 
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Introduction
Small vessel vasculitis (SVV) is characterized by an inflammation of venules,
capillaries, arterioles and sometimes arteries.1 It includes various forms of immune
complex-mediated vasculitis, such as Henoch-Schönlein purpura and
cryoglobulinemic vasculitis, and forms of necrotizing vasculitis characterized by the
(near) absence of immune deposits, such as Wegener’s granulomatosis and
microscopic polyangiitis.1 Most cases of these so called pauci-immune SVV are
associated with anti-neutrophil cytoplasmic antibodies (ANCA). Renal involvement,
histologically characterized by a necrotizing and crescentic (extracapillary)
glomerulonephritis, is often found in patients with pauci-immune SVV.2 Clinically
patients present with a rapidly progressive glomerulonephritis (RPGN). Based on
the presence of the above mentioned ANCA antibodies, patients with idiopathic
crescentic glomerulonephritis without systemic involvement are considered to be
part of the vasculitis disease spectrum: for these patients the term renal limited
vasculitis has been used. Between 20 and 40% of patients with pauci-immune renal
vasculitis develop end stage renal disease (ESRD).3;4 Anti-glomerular basement
membrane (GBM) disease is another, less frequent, cause of necrotizing crescentic
glomerulonephritis. The disease rapidly causes severe renal failure and renal
survival is poor, with 65% of patients developing ESRD.5 Pauci-immune SVV and
anti-GBM disease not only have similar clinical manifestations, but between 10 and
38% of patients with anti-GBM disease also have a positive ANCA test.6
Renal transplantation is the preferred treatment option for patients with ESRD.
Several studies have indicated that renal transplantation can be successful in
patients with vasculitis or anti-GBM disease. However, recurrent disease after
transplantation has also been described. Based on case series the recurrence rate
of ANCA-associated small vessel vasculitis after renal transplantation varies
between 11-50%.3;7-14 In a recent pooled analysis by Nachman et al. the overall
risk of recurrent ANCA-associated SVV after renal transplantation was 17%.15 Most
of these studies have been restricted to patients with Wegener’s granulomatosis
and microscopic polyangiitis. Recurrence of the underlying disease and graft failure
in patients with renal limited vasculitis has, to our knowledge, rarely been studied.
Recurrence of anti-GBM nephritis is related to the presence of anti-GBM antibodies.
Histologic recurrence rate in transplants is about 50% if transplantation is
performed while circulating antibodies are still present.16;17 The recurrence rate
decreases to 5-15% if transplantation is postponed for at least 6 months after the
disappearance of antibodies.18
Most studies on renal transplantation in patients with pauci-immune SVV and anti-
GBM disease did not involve more than 25 patients. In our center 43 patients with
pauci-immune SVV and anti-GBM disease have received a renal transplant since 1968.
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This has provided us with the opportunity to study a larger group of patients with
pauci-immune SVV and anti-GBM disease. The aim of this retrospective study was
to evaluate the outcome of renal transplantation in patients with pauci-immune SVV
and anti-GBM disease, to assess the rate of relapse of pauci-immune SVV and anti-
GBM disease and to compare the outcome of transplantation in patients with pauci-
immune SVV and anti-GBM disease with a matched control group from our hospital. 
Methods
We have examined the records of patients diagnosed with crescentic
glomerulonephritis, who received a kidney transplant in our hospital, between 1968
and 2000. Patients younger than 15 years at the time of transplantation were
excluded. For this study only patients with biopsy proven pauci-immune crescentic
glomerulonephritis or anti-GBM disease were included. Patients with pauci-immune
extracapillary glomerulonephritis were classified as Wegener’s granulomatosis (WG)
or microscopic polyangiitis (MPA) according to the criteria of the American College
of Rheumatology and the Chapel Hill criteria.19;20 All patients with WG and MPA had
signs of systemic vasculitis defined as: fever, night sweats, arthralgia, myalgia,
stridor, hoarseness, oral ulcers, purulent or bloody nasal discharge, hemoptysis,
pulmonary hemorrhage,  new expanding pulmonary nodules without evidence of
infection, iritis or uveitis, new mononeuritis multiplex, necrotising vasculitis
identified by tissue biopsy of any tissue other than the kidney. Patients who only
had a pauci-immune extracapillary glomerulonephritis without signs of systemic
vasculitis were classified as renal limited vasculitis (also called idiopathic necrotizing
crescentic glomerulonephritis).  
From 1968 to 1983 basic immunosuppressive therapy after transplantation
consisted of prednisone (25 mg/day for 1 month tapered to 10 mg/day after 4
months) and azathioprine (3 mg/kg/day). From 1983 to 1985 patients were treated
in a randomized study with either cyclosporine A (CsA; starting with 17.5
mg/kg/day and tapering to 5 mg/kg/day at 3 months) and prednisone for the first
3 months followed by conversion to azathioprine and prednisone thereafter, or
azathioprine and prednisone for the whole period.21 From 1985 to 1989 all patients
received CsA and prednisone during the first 3 months after transplantation and
azathioprine and prednisone thereafter. In the period from 1989 to 1992, patients
were treated with CsA (starting with 12 mg/kg/day and tapering to 4 mg/kg/day
at 3 months) and prednisone for the first 3 months and thereafter randomized for
continued treatment with either azathioprine and prednisone or CsA monotherapy.22
From 1992 to 1997 patients were treated with the combination of CsA and
prednisone and from 1997 to 2000 patients have been treated in a randomized
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study with mycophenolate mofetil (MMF; 1g bid), prednisone and high (10
mg/kg/day) or low dose (6 mg/kg/day) CsA.23 Since 2000 patients are treated with
tacrolimus and mycophenolate mofetil in combination with either prednisone or
daclizumab. Patients who received an HLA-identical living related donor kidney have
been treated with different immunosuppressive regimens. Until 1985 these patients
received azathioprine and prednisone. Thereafter they have been treated with CsA
(starting with 12 mg/kg/day and tapering to 4 mg/kg/day at 3 months) and
prednisone for the first three months, followed by conversion to azathioprine and
prednisone.   
The following data were documented from the patient records: gender, age, onset
of disease, clinical symptoms, presence of ANCA or anti-GBM antibodies, renal
biopsy result, number of transplants, follow-up time after transplantation (follow-
up was calculated until death of the patient or renal allograft failure), age at
transplantation, donor source, age of donor, cold ischemia time, occurrence of
delayed graft function, number of mismatches at HLA-A, B and DR loci,
immunosuppressive therapy, relapse rate, malignancy, graft failure and patient
survival. 
A patient was considered to have a relapse of vasculitis if at least one of the following
criteria occurred: a renal biopsy demonstrating active necrosis or crescent
formation; necrotising vasculitis identified by any tissue biopsy; hemoptysis,
pulmonary hemorrhage or new or expanding pulmonary nodules without evidence
of infection; iritis or uveitis; new mononeuritis multiplex.4;24 A relapse of anti-GBM
nephritis was defined as: pulmonary hemorrhage and/or a renal biopsy
demonstrating linear deposits of IgG in the glomerular basement membrane and/or
four-fold increase in anti-GBM antibodies.
For each patient with pauci-immune glomerulonephritis or anti-GBM nephritis, two
control patients were selected from our database. The controls were matched for
age, gender, time of transplantation, donor source. Patients with diabetes or
systemic lupus erythematosus were excluded.
Statistical analysis
The values are given as mean ± SD or median and range when appropriate. For
comparison between groups unpaired T-test or Mann-Whitney U test were used.
Patient and graft survival rates were calculated with Kaplan-Meier survival curves.
Log-rank test was used for comparison of survival curves and the incidence of
malignancies. Analysis of the incidence of malignancies was censored for graft failure
and death of the patient. A P-value of 0.05 was considered as the level of statistical
significance.
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Results
We have identified 43 patients (31 male and 12 female) with either pauci-immune
SVV or anti-GBM disease, who received a first allograft in our hospital. Eight patients
had Wegener’s granulomatosis, 7 patients had microscopic polyangiitis, 18 patients
had renal limited vasculitis and 10 patients had anti-GBM disease. Six patients with
Wegener’s granulomatosis, 4 patients with microscopic polyangiitis and 7 patients
with renal limited vasculitis were tested for ANCA, all patients were positive. Except
for one patient, the sixteen patients, who were not tested, developed their disease
before 1987. Until that time ANCA titers were not routinely determined. All 10
patients with anti-GBM disease had serum anti-GBM antibodies. Demographic data
are shown in table 1. The interval between the onset of disease and dialysis was
significantly longer in patients with pauci-immune SVV compared to patients with
anti-GBM disease. For transplantation characteristics see table 2. Six patients
received a graft from a living donor, which was haplo-identical in 4 and mismatched
in 2 patients. Twelve controls received a graft from a living donor, which was haplo-
identical in 9 patients and HLA-identical in 1 patient. Data regarding HLA A and B
mismatches were available for all grafts, mismatches on HLA DR were not available
for one graft. The mean number of mismatches (A, B, DR) was 0.8 ± 0.7. 
During chronic hemodialysis treatment three patients with Wegener’s
granulomatosis had four episodes of recurrence with involvement of the upper
respiratory tract, joints, lungs and gut. After treatment with cyclophosphamide and
prednisone the symptoms disappeared. 
All but 8 patients with pauci immune SVV were treated with immunosuppressive
therapy (prednisone and/or cyclophosphamide), for a mean of 17 ± 15 months.
Furthermore all patients with anti-GBM disease were treated with
immunosuppressive therapy for a mean of 3 ± 2 months. Prior to transplantation,
patients with pauci-immune SVV were without immunosuppressive therapy for a
median of 20 months (range 0-110 months), patients with anti-GBM disease were
without therapy for a median of 18 months (range 5-57 months). 
At the time of transplantation patients with anti-GBM disease were significantly
younger than patients with MPA (P=0.02) and renal limited vasculitis (Table
1;p=0.04). Around the time of transplantation 18 patients were tested for ANCA’s,
six with Wegener’s granulomatosis, four with microscopic polyangiitis and eight
with renal limited vasculitis. Positive ANCA’s were found in two patients with
Wegener’s granulomatosis (titers between 1:16 and 1:32), two patients with
microscopic polyangiitis (titers 1:16) and four patients with renal limited vasculitis
(titers between 1:8 and 1:32). Anti-GBM antibodies were tested in six patients with
anti-GBM disease, only one patient was weakly positive (titer 1:8). No patient had
evidence of active disease.
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Few patients (n=6) were tested for ANCA more than one year after transplantation,
5 patients were negative and only one patient was positive (titer 1:64).
During follow-up after transplantation only one patient with Wegener’s
granulomatosis had extrarenal recurrence of his disease, 5 months after
transplantation. Immunosuppressive therapy consisted of tacrolimus and MMF.
Symptoms were sinusitis, bloody nasal discharge and mononeuritis multiplex. The
ANCA titer remained low (< 1:16) and did not increase. After treatment with
trimethoprim-sulfamethoxazole the symptoms diminished. A total of 27 patients
developed renal dysfunction as reflected by a rise of serum creatinine. A renal biopsy
was performed in 21 patients, disclosing a rejection (n=15) or ciclosporin toxicity
(n=6) as cause. Specifically, in no single biopsy there was any evidence of vasculitis.
The other six patients responded promptly to antirejection treatment, thus
obviating the need for a biopsy. Ten patients have developed a period of fever, which
was attributed to an infection. In 8 patients a micro-organism was identified, in 2
remaining patients there was a response to antimicrobial therapy. Taken together,
it is unlikely that recurrent disease has been missed.
In the study group patient survival was 92%, 88% and 77% at one, three and five
years respectively (figure 1a). Data for the subgroups are given in table 3.  Fifteen
patients (35%) died. No patient died due to recurrence of vasculitis or anti-GBM
disease. Two patients with Wegener’s granulomatosis died due to a documented
infection, three patients with microscopic polyangiitis and one patient with anti-GBM
disease died because of cardiac disease. One patient with Wegener’s granulomatosis,
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Figure 1a Patient survival after renal transplantation in patients with pauci-immune SVV or anti-GBM
disease (–––––) compared to the control group (-----).
Figure 1b Graft survival after renal transplantation in patients with pauci-immune SVV or anti-GBM
disease (–––––) compared to the control group (-----).
bw.van leeuwen  12-07-2005  10:34  Pagina 89
one with anti-GBM disease and one with renal limited vasculitis died due to an identified
malignancy. Five patients (four with renal limited vasculitis and one with microscopic
polyangiitis) died of other identifiable causes and from only one patient with renal
limited vasculitis the exact cause of death could not be retrieved. 
Graft survival in the study group was 83% at one year, 72% at three years and
60% at five years (figure 1b). Data for the subgroups are given in table 3. Eleven
grafts (23%) were lost after the first transplantation. None of the patients lost their
graft due to recurrence of vasculitis or anti-GBM nephritis. Four patients with renal
limited vasculitis and two patients with anti-GBM disease lost their grafts because
of chronic rejection, two patients with renal limited vasculitis and one patients with
anti-GBM disease lost their grafts due to arterial thrombosis, one patient with anti-
GBM disease lost her graft because of an infection of the renal graft and one patient
with renal limited vasculitis developed a renal cell carcinoma in the renal graft. 
Seven patients received a second graft, five with renal limited vasculitis and two
with anti-GBM disease. Two out of the seven regrafts (29%) were lost, average
time until failure of the second graft was 34 ± 25 months. One patient with renal
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Table 3 Patient and graft survival for subgroups of patients with pauci-immune small
vessel vasculitis or anti-GBM disease.
Wegener’s MPA Renal limited Anti-GBM
granulomatosis vasculitis disease
Patient survival
1-year 86%     86%              93%                100%
3-year 86% 86% 85% 100%
5-year 51% 69% 85% 100%
Graft survival
1-year 86%                86%             76%                 90%
3-year 86% 86% 63% 68%
5-year 51% 69% 63% 54%
MPA: microscopic polyangiitis
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limited vasculitis lost his graft because of chronic rejection and one patient with
anti-GBM disease lost his graft due to acute rejection.
The control group consisted of 86 patients, 61 males and 25 females. The mean
age at transplantation was 47 ± 14 years. For donor characteristics see table 2.
Patient survival in the control group was 96%, 85% and 79% at one, three and
five years respectively (figure 1a). Graft survival after first transplantation in the
control group was 80% at one year, 67% at three years and 56% at five years
(figure 1b). Neither patient survival nor graft survival differed significantly between
patients with pauci-immune SVV or anti-GBM disease and the control group. 
In the study group twelve patients (28%) developed a malignancy after
transplantation, eight (19%) patients had skin cancer, one cervical cancer, one
developed lung cancer, one patient had an esophageal carcinoma and one patient
developed a renal cell carcinoma of the renal graft. Nine patients (10%) in the
control group developed a malignancy, four (5%) patients had skin cancer, three
patients developed a non-Hodgkin lymphoma, one had a pancreas carcinoma and
one patient had a carcinoma of the mouth. Malignancies were significantly more
frequent in the study group (Odds ratio 2.82, 95% C.I. 1.18-6.71, p=0.02). The
difference could be attributed to the increased incidence of skin cancers (Odds ratio
4.50, 95% C.I. 1.35-15.15, p=0.006). Other malignancies developed in 4 patients
(9%) in the study group and in 5 control patients (6%, Odds ratio 1.69, 95% C.I.
0.45-6.29, p=0.45). 
Discussion
We have studied 43 patients with pauci-immune SVV or anti-GBM disease, who
received a renal transplant between 1968 and 2000 in our center. As expected, at
the time of transplantation patients with anti-GBM disease were younger than
patients with pauci-immune SVV. This is due to the younger age at which the disease
occurs and the fact that it rapidly progresses to ESRD. This is confirmed by the fact
that the patients with anti-GBM disease in our study, almost immediately needed
renal replacement therapy.  
Recurrence of the original disease was rare in our patients. Only one patient with
Wegener’s granulomatosis developed a relapse with evidence of involvement of
extrarenal organs. Specifically, we did not observe a renal recurrence in any of our
patients. Most patients with renal allograft dysfunction were biopsied and no
evidence of vasculitis was found. Furthermore, in almost all patients with fever a
responsible micro-organism was identified. 
In the literature the reported rate of recurrence in patients with pauci-immune SVV
ranges from 11-50%.7-14 These percentages evidently exceed the 3% in our study.
However, most literature data involve patients with systemic disease i.e. Wegener’s
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granulomatosis and microscopic polyangiitis. If we only consider our patients with
systemic vasculitis, recurrence rate is 7% (95% C.I. 0-30%). This is compatible
with the 17% recurrence rate reported in the pooled analysis.15 Moreover, our
patients were free of disease activity for a long period before transplantation.
Furthermore, in the pooled analysis small case series were included that reported
a 50% recurrence rate. It is likely that selective publication of cases with recurrent
disease results in a higher estimate of the risk of recurrent disease.
The patient with recurrence of Wegener’s granulomatosis was one of two patients
with a positive ANCA around the time of transplantation, although the ANCA titer
was low with 1:16. During relapse of his disease the ANCA titer did not rise. A
positive ANCA at the time of transplantation was present in four patients with
microscopic polyangiitis. Since only one patient relapsed after transplantation we
are not able to determine if a positive ANCA is associated with an increase in the
frequency of relapses. Of note, most patients if not all were free of disease activity
at the time of transplantation. Literature data suggest that the presence of ANCA
at transplantation is not associated with an increased rate of relapse after
transplantation.16
Four relapses occurred before transplantation, all in patients with Wegener’s
granulomatosis. It is likely that the use of immunosuppressive therapy after
transplantation contributes to control of the original disease.
No patient with renal limited vasculitis developed recurrent disease. Nyberg et al.25
have reported similar results, none of their 25 patients with renal limited vasculitis
had recurrent disease. However, on 23 patients in the study by Nyberg et al. detailed
information is lacking, thus patients with immune complex mediated rapidly
progressive glomerulonephritis may have been included. Other information on
recurrence of disease in patients with renal limited vasculitis is scarce. In their
overview on recurrent glomerulonephritis after renal transplantation, Kotanko et
al. report a low recurrence rate between 1.3 and 1.7%.18 Based on our results and
the above-mentioned studies, it seems reasonable to state that renal transplantation
can be safely performed in patients with renal limited vasculitis and that recurrent
disease in this subgroup is uncommon. 
Also, no relapse occurred in our patients with anti-GBM disease. Most reviews report
a recurrence rate of 5-15%, based on old data. There are few recent data in the
literature on recurrent anti-GBM disease after renal transplantation. The lack of
recent data point to an even lower recurrence rate of anti-GBM disease. Cameron
already concluded that the rate of clinical recurrence may be less than 5%, provided
that anti-GBM antibodies are undetectable at the time of transplantation.26 This
and our conclusion is supported by two more recent publications, which included
10 patients with anti-GBM disease.4;10 In these studies no graft failed due to
recurrent anti-GBM disease. 
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To ascertain that the original renal disease has no major impact on the course after
transplantation, we have compared patient and graft survival in our study
population with survival of a matched control group. Patient and graft survival in
our patients with pauci-immune SVV and anti-GBM disease were equivalent to
patient and graft survival in a matched control group. When compared to other
studies patient survival in our study group is lower. Several studies report patient
survival rates between 85 and 94% after 5 years.7;10;25 However, this difference
can probably be explained by the younger age at transplantation in these studies.
These data underline that transplantation is as good a treatment option in patients
with vasculitis as in other patients. 
It is well known that after transplantation the incidence of malignancies increases,
with skin cancer being the most common malignancy in renal transplant recipients.27
Our data clearly indicate that the risk of developing a malignancy is significantly
higher in patients with pauci-immune SVV or anti-GBM. A likely explanation for
this difference is that patients with pauci-immune SVV or anti-GBM already received
immunosuppressive therapy prior to transplantation. Our data are in agreement
with the data of Hibberd et al., who found that pretransplant immunosuppression
increased the risk of developing carcinomata of the cervix, vagina, vulva and non-
Hodgkin lymphoma.28 The article does not report the incidence of skin malignancies.
To our knowledge the effect of pretransplant immunosuppression on the
development of malignancies has not been studied very often. It is important to
notice that in our study the increased number of malignancies did not influence
patient survival, which can be attributed to the fact that the majority of cancers
involved the skin.       
In summary, renal transplantation can be successfully performed in patients with
ESRD secondary to pauci-immune SVV or anti-GBM disease. Patient and graft
survival are comparable to those of patients with other causes of ESRD and
recurrence of the underlying disease is rare. Renal transplant patients with pauci-
immune SVV or anti-GBM disease are at increased risk for developing skin
malignancies. 
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Abstract
Renal transplantation is considered to be a good treatment option for patients with
systemic lupus erythematosus (SLE) and end-stage renal disease. However, in
patients with glomerular diseases, the outcome of renal transplantation can be
adversely affected by recurrence of the original disease. Furthermore, the
posttransplant course might be complicated by pretransplant morbidity and
treatment history. We have studied the outcome of renal transplantation in patients
with SLE, transplanted in our center between 1968 and 2001. Patient and graft
survival were compared with a matched control group. We specifically looked for
any evidence of recurrent disease. 
There were 23 patients (2 male, 21 female) with a mean age of 34 ± 12 years at
transplantation. One patient developed renal failure with serological evidence of
SLE activity, 61 months after transplantation. In the absence of urine abnormalities
we favored a diagnosis of rejection, although recurrence of lupus nephritis could
not be excluded formally. This was the only case with a possible recurrence of lupus
nephritis. Two other patients developed extrarenal manifestations of SLE, at 6 and
17 months after transplantation. Patient and graft survival rates, 5 years after
transplantation were 86% and 68% respectively. Survival rates were not
significantly different from those of a matched control group, 90% and 78%
respectively.   
Clinical recurrence of SLE after transplantation is rare. The results of renal
transplantation in patients with SLE do not differ significantly from a matched control
group. Renal transplantation is a good alternative for renal replacement therapy
in patients with lupus nephritis. 
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Introduction
Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disorder that
is characterized by the production of antibodies against auto-antigens, in particular
nuclear, cytoplasmatic and cell membrane antigens. SLE can affect multiple organ
systems including the kidney. Lupus nephritis is one of the most serious
manifestations of the disease and overt nephritis is found in up to 60% of adults
with SLE.1;2 End stage renal disease (ESRD) requiring hemodialysis or renal
transplantation develops in 5-22% of patients with lupus nephritis.3 Transplantation
is considered a good therapeutic option for patients with ESRD due to lupus
nephritis, although recurrent disease may occur more frequently than initially
thought.4 The reported recurrence rate of lupus nephritis ranges from less than 1
to 8%.5;6
Most studies have reported equal graft survival rates in patients with lupus nephritis
compared to patients with other underlying diseases.7-11 However recent data have
suggested that graft survival in renal transplant patients with SLE may be less,6;12
especially in cadaveric allograft recipients treated with cyclosporine.13
The aim of this retrospective study was to evaluate the outcome of renal
transplantation in patients with SLE and to assess the rate of relapse of SLE. 
Materials and Methods
We examined the records of patients diagnosed with lupus nephritis, who received
a kidney transplant at our hospital between 1968 and 2001. Patients younger than
15 years at the time of transplantation were excluded. Only patients who fulfilled
at least four of the criteria defined by the American Rheumatism Association were
included in the study.14;15
From 1968 to 1983 basic immunosuppressive therapy consisted of prednisone (25
mg/day for 1 month tapered to 10 mg/day after 4 months) and azathioprine (3
mg/kg/day). From 1983 to 1985 patients were treated in a randomized study with
either cyclosporine A (CsA; starting with 17.5 mg/kg/day and tapering to 5
mg/kg/day at 3 months) and prednisone for the first 3 months followed by
conversion to azathioprine and prednisone thereafter, or azathioprine and
prednisone for the whole period.16 From 1985 to 1989 all patients received CsA
and prednisone during the first 3 months and azathioprine and prednisone
thereafter. In the period from 1989 to 1992, patients were treated with CsA (starting
with 12 mg/kg/day and tapering to 4 mg/kg/day at 3 months) and prednisone for
the first 3 months and thereafter randomized for continued treatment with either
azathioprine and prednisone or CsA monotherapy.17 From 1992 to 1997 patients
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were treated with the combination of CsA and prednisone, and from 1997 patients
have been treated in a randomized study with mycophenolate mofetil (MMF; 1 gr.
bid), prednisone and high (10 mg/kg/day) or low dose (6 mg/kg/day) CsA.18 Since
2000 patients are treated with tacrolimus and mycophenolate mofetil in combination
with either prednisone or daclizumab. Patients who received an HLA-identical living
related donor kidney have been treated with different immunosuppressive
regimens. Until 1985 these patients received azathioprine and prednisone.
Thereafter they have been treated with CsA (starting with 12 mg/kg/day and
tapering to 4 mg/kg/day at 3 months) and prednisone for the first three months,
followed by conversion to azathioprine and prednisone.  
The following data were documented from the patients’ records: gender, age, onset
of disease, onset of clinical renal disease defined as proteinuria of more than 0.5
g/24h or urinary sediment abnormalities (according to the ARA criteria for SLE),
clinical symptoms, presence of ANA (anti nuclear antibodies), anti-double-stranded
DNA (anti-dsDNA), antiphospholipid antibodies, duration of dialysis prior to
transplantation, renal biopsy result, follow-up time after transplantation, age at
transplantation, donor source, age of donor, number of mismatches at the HLA-A,
B and DR loci, immunosuppressive therapy, relapse rate, malignancy, graft failure
and death of patient, coronary heart disease (myocardial infarction, angina
pectoris), stroke, and peripheral vascular disease (aortic aneurysm, intermittent
claudication). For each patient with SLE, one control patient was selected from our
database. The controls were matched for age, gender, time of transplantation and
donor source. Information obtained from the control patients included: gender, age,
donor source, age of donor, original disease, transplantation day, follow-up time
after transplantation, age at transplantation, malignancy, date and cause of graft
failure and death of patient.
Statistical analysis
The values are given as mean ± SD or median (range) when appropriate. For
comparison between groups unpaired t-test or Mann-Whitney U test were used for
continuous data and Fisher’s exact test was used for categorical data. Patient and
graft survival rates were calculated with Kaplan-Meier survival curves. The log-rank
test was used for comparison of survival curves and the incidence of cardiovascular
events. A P-value of 0.05 was considered as the level of statistical significance.
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Results
We have identified 23 patients (two male and 21 female) with lupus nephritis, who
received a first renal allograft in our hospital. Twenty patients were Caucasian, one
patient was Moroccan and two patients were black. Characteristics of the individual
patients at the time of the diagnosis of SLE and at transplantation are given in table
1 and 2. The SLE disease activity index, and the presence of ANA and anti-dsDNA
is given in table 3.   
Mean time between the onset of SLE-nephritis and ESRD was 70 ± 13 months, and
mean time on dialysis was 30 ± 5 months. Before transplantation all 23 patients
have been treated with prednisone for a mean of 9.3 ± 5.4 years. Seventeen
patients continued using prednisone during dialysis until transplantation.
Furthermore, before dialysis, 15 patients received concomitant treatment with
azathioprine for a mean of 4.5 ± 4.7 years and three patients were treated with
cyclosporine. In the early course, before the onset of ESRD, ten patients had 20
flares of disease activity of SLE, seven at extrarenal sites and 13 involving the kidney.
The flares were treated with more intensified immunosuppressive therapy; however
only 3 patients have been treated with cyclophosphamide. During chronic dialysis
no patient had new flares of SLE activity. 
Around the time of transplantation 17 patients were tested for ANA. A positive ANA
was found in 10 patients. Anti-dsDNA was tested in 13 patients, only two patients
(who were also positive for ANA) were positive, with relatively low titers of 63 and
29 U/l respectively.   
Follow-up time after transplantation was 74 ± 72 months. After transplantation,
two patients had evidence of extrarenal SLE disease activity, whereas another
patient had a probable recurrence of lupus nephritis. The first patient (no 5)
developed arthritis of the right ankle at 17 months after transplantation while
receiving maintenance immunosuppressive therapy that consisted of cyclosporine
and prednisone. Physical examination revealed a red, swollen right ankle. Synovial
fluid could not be aspirated. The anti-dsDNA titer increased from 42 U/ml to 79
U/ml. Before transplantation anti-dsDNA was also positive with a titer of 30 U/ml.
The patient was treated with a transient increase in prednisone dose and
azathioprine was added to the maintenance immunosuppressive regimen. With this
treatment her symptoms subsided and the anti-dsDNA became negative. 
The second patient (no 23) had suffered three flares of disease activity of SLE (two
involving the kidney and one at extrarenal sites) before transplantation. The
extrarenal flare consisted of a malar rash, oral ulcers, arthritis and a positive anti-
dsDNA titer of 500 U/ml. The last flare, a reactivation of her lupus nephritis, occurred
one year before transplantation. Six months after a living-related donor
transplantation she presented with ataxia, paralysis of the facial nerve, arthritis and
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skin lesions. Immunosuppressive therapy consisted of prednisone and cyclosporine.
Anti-dsDNA was initially negative, but became positive with 33 U/l, complement levels
remained normal. MRI of the brain showed a lesion in the basal ganglia consistent
with ischemia due to extensive arteritis. The symptoms diminished spontaneously
and anti-dsDNA titers became negative again. Seven months later she suffered from
a grand mal insult probably related to SLE. Although anti-dsDNA titers remained
negative, a CT scan of the brain showed an increase in the lesions in the basal ganglia,
consistent with extensive vasculitis. Blood pressure was very high at 240/130 mmHg,
and laboratory studies revealed an increase in creatinine and thrombocytopenia,
without micro-angiopathic hemolytic anemia. Fundoscopic examination was normal.
A renal biopsy showed thrombi in the arterioles and the glomeruli without signs of
lupus nephritis. Immunofluorescence of the renal biopsy was consistent with
intravascular coagulation. No lupus anticoagulant activity or anticardiolipin antibodies
were detected. The grand mal insults responded well to treatment with high doses
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of methylprednisolone, but the renal function deteriorated further, necessitating
hemodialysis. 
The patient who developed a probable recurrence of lupus nephritis (no 7) received
a cadaveric graft after 21 months on hemodialysis. Pretransplant serology showed
an anti-dsDNA titer of < 1:20 (negative) and normal complement. Post-transplant
immunosuppressive therapy consisted of prednisone and azathioprine. Sixty-one
months after transplantation, she developed edema, a proteinuria of 0.5 gram/day,
and a new butterfly rash. Urinalysis did not show any erythrocytes. Laboratory studies
revealed an elevated creatinine of 4.1 mg/dl , a C3 level of 514 mg/l (normal: 750-
1250 mg/l), a C4 level of 63 mg/l (normal: 180-400 mg/l), and a positive ANA.
Because of a prolonged bleeding time, no renal biopsy was performed. The activated
partial thromboplastin time and prothrombin time were normal. The patient was
treated with prednisone (0.5 mg/kg per day). Initially serum creatinine level declined
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to 2.7 mg/dl and the C3 and C4 level increased to 827 mg/l and 142 mg/l,
respectively. However, after two months the creatinine level increased again with
no response to high doses of prednisone (1.5 mg/kg per day). Because of graft failure,
she was subsequently placed on CAPD. Four months after graft failure she was
admitted to the hospital for acute operative repair of an aneurysm of the thoracic
aorta. Postoperatively she died due to sepsis. Post-mortem examination was refused.
In the SLE group, overall patient survival was 86%, 86% and 51% at 1, 5 and 10
years respectively (figure 1). Seven patients (30%) died with functioning allografts.
No patient died due to recurrence of SLE. Causes of death were: infections (n=4),
myocardial infarction (n=1), cerebral hemorrhage (n=1), and malignancies (n=1).
Graft survival was 78% at 1 year, 68% at 5 years and 38% at 10 years (figure 2).
Five grafts were lost after transplantation. Graft failure was caused by recurrent
lupus nephritis (n=1; case no 7), chronic rejection (n=1), arterial and venous
thrombosis as a complication of compression by large hematomas due to direct
postoperative bleeding at the anastomosis (n=1), acute rejection (n=1) and
intraglomerular thrombosis (n=1; patient no 23). Graft survival for cyclosporine
treated patients with a cadaveric graft (n=7) was 75% at 1 and 5 years.
The control group consisted of 23 patients, three males and 20 females. Mean age
at transplantation was 35 ± 13 years. The original disease was chronic pyelonephritis
(n=6), polycystic kidney disease (n=3), hemolytic uremic syndrome (n=1),
membranoproliferative glomerulonephritis (n=3), membranous glomerulopathy
(n=2), interstitial nephritis (n=1), Alport syndrome (n=1), IgA nephropathy (n=1),
reflux nephropathy (n=1), and unknown (n=4).  The control group was comparable
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Figure 1 Patient survival after renal transplantation in patients with SLE (–––––) and in the control
group (-----).
Figure 2 Graft survival after renal transplantation in patients with SLE (–––––) and in the control group
(-----).
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to the SLE group with respect to several donor and transplant characteristics (table
4). Patient survival in the control group was 95%, 90% and 77% at 1, 5 and 10
years respectively (figure 1). Graft survival in the control group was 83% at 1 year,
78% at 5 years and 46% at 10 years (figure 2). Graft survival in the cyclosporine
treated control group with cadaveric grafts (n=8) was 75% after 1 and 5 years.
Although survival rates were numerically lower in SLE patients, the difference did
not reach statistical significance. There was also no statistical significant difference
in graft survival of pre-cyclosporine-era and post-cyclosporine-era lupus cadaver
grafts compared to controls. 
In the study group three patients (13%) developed a malignancy after transplantation,
one patient had skin cancer, one had cervical cancer (carcinoma in situ), and one
developed breast cancer. Seven patients (30%) in the study group suffered from
vascular disease. Five patients developed coronary heart disease, one patient had
peripheral vascular disease, and one patient died because of a stroke. Three patients
(13%) in the control group developed a malignancy, one had skin cancer, one
developed a renal cell carcinoma, and one had lung cancer. Two patients in the control
group suffered from vascular disease, one had coronary artery disease necessitating
a coronary artery bypass graft, and one developed a stroke. The difference between
cardiovascular events in the SLE group and the control group just failed to reach the
level of statistical significance (figure 3; p=0.07).  
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Table 4  Donor and transplantation characteristics of SLE patients and controls
SLE Controls
(n=23) (n=23)
Donor Source
Postmortal     19          19
LRD  4  4
Donor age (years) 35 ± 18 45 ± 20
Donor sex (M/F) 9/13* 15/8
Cold ischemia time (hours) 21± 13 24 ± 13
Acute tubular necrosis (n)  5 11
Acute rejections (n) 21 22
Follow-up (months) 74 ± 73 85 ± 75
Mean HLA mismatch 0.7 ± 0.6 0.6 ± 0.5
No significant differences;LRD: living-related donor; * The gender of one donor could not be retrieved.
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Discussion
We have studied 23 patients with SLE, who received a renal transplant between
1968 and 2001. Three patients (13%) experienced SLE disease activity after
transplantation. A possible relapse of lupus nephritis occurred in only one patient
(4%). We have no histological prove of the recurrence of lupus nephritis and the
absence of erythrocytes in the urine sediment argues against lupus nephritis.
However, the development of renal insufficiency and proteinuria was accompanied
by a new butterfly rash, decreased serum complement levels, and a positive ANA.
Therefore, to circumvent bias against under-reporting recurrence rates, we
attributed graft failure to possible lupus nephritis, although a rejection process may
seem more likely. The recurrence rate in our study group is compatible with the
recurrence rates of lupus nephritis reported in the literature, which varies between
<1 and 8%. For a long period of time it was thought that lupus nephritis had one
of the lowest rates of recurrence.1 Until 1998, there were only seven reported cases
of biopsy proven recurrent lupus nephritis in a total of 331 patients, implying a
recurrence frequency of 2.1%.12 However, this estimate may be too low. In a more
recent study by Stone et al. in 97 renal transplant patients with SLE, the recurrence
rate of lupus nephritis was higher, reaching 8.5%.19 The lower recurrence rate in
earlier reports is probably due to difficulties in distinguishing recurrent lupus
nephritis from other causes of graft failure. Also, in most studies evaluation of
recurrent disease was not the primary question. Admittedly, recurrence of lupus
nephritis still remains a relatively rare cause of renal allograft loss.  
We have only limited data on the value of routine serological evaluation during
follow-up of SLE patients. However, the low recurrence rate suggests that routine
laboratory follow-up is not necessary and is only indicated in case of signs or
symptoms compatible with SLE disease activity.
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Our study showed no significant difference in overall graft survival in patients with
ESRD due to lupus nephritis and the control group. This conclusion was not altered
when we analyzed data for the pre-cyclosporine and postcyclosporine eras. Since
only four patients received a living-related renal transplant, we are not able to
determine whether or not graft survival in these patients is better. Several other
studies have been published on graft survival in lupus patients, with varying results.
A number of small studies have shown that graft survival in lupus patients is similar
to that of a control population.7-11;20-22 A large study conducted within the US Renal
Data system, in which comparisons were adjusted for confounding factors, reported
that both cadaveric and living related-donor graft survival in 1162 patients with
lupus nephritis was equivalent to graft survival in controls.22 However, other studies
have reported poorer graft survival in lupus patients.6;13;23-26 These conflicting
results may be due to differences in the composition of the control groups, since
only few studies on renal transplantation in lupus patients used matched controls.6;11
Another explanation could come from differences in type of immunosuppression.
Several studies have found lower allograft survival in lupus patients in the
cyclosporine era. Most of these patients received a cadaveric graft.6;24 Lochhead
et al. reported a significantly lower 5-year graft survival for cyclosporine-treated
recipients of cadaveric grafts than for controls and for cyclosporine-treated living
allograft recipients.13 Few studies have actually compared graft survival in SLE
patients before and after the introduction of cyclosporine. Overall graft survival in
these studies is higher for patients being treated with cyclosporine than for those
on azathioprine, although there is no statistical significant difference.11;26 A study
by Zara et al. reported a significantly higher 1-year graft survival rate in
cyclosporine-treated patients with a cadaveric graft than in patients treated with
azathioprine, namely 62% and 26%, respectively.27 These studies indicate that
immunosuppression with cyclosporine after cadaveric or living related-donor renal
transplantation in patients with lupus nephritis is at least as good as azathioprine.
Donor source may also cause differences in graft survival. Living related-donor grafts
seem to do better than cadaveric grafts, although only Lochhead et al. reported a
statistical significant difference.10;13;22;27 Due to the heterogeneity of all these
studies it is difficult to draw definitive conclusions about the risk of graft failure in
patients with lupus nephritis. Based on studies with poorer rates of graft survival
after postmortal renal transplantation, it has been suggested that dialysis might
be preferable for patients with ESRD due to lupus nephritis, for whom no living-
related donor is available.13 However, although one might conclude that living
related-donor transplantation is the preferred treatment option for patients with
ESRD due to lupus nephritis,4;12 postmortal donor transplantation is still a good
treatment option. Our own study and a number of other studies, including the largest
study to date by Ward et al., have clearly shown that graft survival after cadaveric
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renal transplantation is equivalent to graft survival in controls.22 Furthermore, the
majority of SLE patients who undergo renal transplantation experience significant
improvements in their quality of life. 
Patient survival in the study population with SLE was not significantly different from
that in the control group, although the 10-year patient survival rate was numerically
lower in patients with SLE. The reported 10-year patient survival in the literature
varies between 60% and 86%.7;13;28 The trend towards poorer 10-year patient
survival rates in our study could be explained by a higher morbidity in patients with
SLE. Although not statistically significant, the high cumulative incidence of
cardiovascular events that we found in our SLE group, compared with controls,
supports the idea of an increased morbidity in the SLE group. Another explanation
could be a higher rate of infection, due to the use of immunosuppressive
medication. Although we did not find a statistically significant difference in the rate
of infections, nevertheless four patients died of sepsis in the SLE group, while no
patient in the control group died of infectious causes. 
The number of malignancies in the study group was the same as that in the control
group. Since patients with SLE have been treated with immunosuppressive
medication before undergoing transplantation, one could expect a higher incidence
of malignancies in the study group. 
In summary, clinical recurrence of lupus nephritis is rare. Although living donor
transplantation might be the preferred treatment option, our study shows that both
postmortal and living related-donor transplantations are good treatment options
for patients with ESRD secondary to lupus nephritis.
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Abstract
Background Chronic allograft nephropathy (CAN) is the leading cause of late allograft
failure, with only limited treatment options. Blockade of the renin-angiotensin
system (RAS) decreases progression in diabetic and non-diabetic renal disease,
but the effect on CAN is yet unclear. Therefore, we have retrospectively studied
the effect of RAS-blockade on renal survival in patients with biopsy-proven CAN.
Methods The medical records of 72 patients with biopsy-proven CAN were evaluated
with regard to time-course of graft function, proteinuria, blood pressure, and
antihypertensive and immunosuppressive treatment. Cox’s proportional hazards
model was used for analyzing renal graft survival after the index biopsy. 
Results On univariate analysis, histological determinants influencing renal survival
were the chronic interstitial and chronic tubular score, and clinical parameters were
the serum creatinine level at the time of the biopsy, the relative change in serum
creatinine level between 12 months posttransplantation and at the time of the
biopsy, mean systolic and diastolic blood pressure after the biopsy, and RAS-
blockade by angiotensin converting enzyme inhibitor or angiotensin receptor
blocker. On multivariate analysis, graft outcome was influenced by the relative
change in serum creatinine level between 12 months posttransplantation and at
the time of the index biopsy, the urinary protein excretion, the mean diastolic blood
pressure after the index biopsy, and RAS-blockade. Renal graft survival after
treatment with RAS-blockade was 6.3 (0.9-10.9) years as opposed to 1.8 (0.1-
6.7) years in untreated patients (p=0.003).
Conclusion RAS-blockade increases graft survival in CAN. In view of the limited
treatment options for CAN this finding is of importance and needs confirmation by
a prospective randomized trial. 
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Introduction
Although the recent introduction of newer immunosuppressive drugs has resulted
in an impressive reduction in the rate of acute rejections after renal transplantation,
the impact of these agents on long-term graft survival is less well established.
Chronic allograft nephropathy (CAN) is still the leading cause of late allograft failure.
Both immunological and non-immunologic factors are involved in the pathogenesis
of CAN and contribute to chronic tubulo-interstitial, glomerular and vascular injury.1
There is no evidence-based treatment of CAN. Most studies focus on limiting or
avoiding the use of calcineurin inhibitors, the use of lipid-lowering or
antihypertensive drugs, or the application of agents with antifibrogenic and
antiproliferative properties.2;3 Angiotensin converting enzyme (ACE)-inhibitors or
angiotensin receptor blockers (ARBs) are of special interest in this respect, since
these drugs attenuate the decline of renal function in patients with diabetic and
non-diabetic renal diseases.4;5 Although these studies provide arguments for the
use of ACE-inhibitors in patients with CAN, firm proof of their benefits is lacking.
Moreover, the use of ACE-inhibitors may pose specific problems, especially in renal
transplant recipients. In case of transplant renal artery stenosis or severe arteriolar
intimal fibrosis acute worsening of graft function can occur after ACE-inhibition.
Furthermore, in a rat model of CAN, the use of an ACE-inhibitor attenuated the
development of focal segmental glomerulosclerosis, but worsened intimal
hyperplasia.6 Finally, RAS-blockade has been associated with anemia and
hyperkalemia. Although Stigant et al. have suggested that both ACE-inhibitors and
ARBs are generally well tolerated in renal transplant recipients with well functioning
grafts,7 side-effects may be more prominent in patients with renal failure. We have
retrospectively studied the effect of RAS-blockade on the rate of progression of
histologically confirmed CAN.
Subjects and methods
Patients
From all patients who received a renal allograft at the University Medical Center
Nijmegen in the period from December 1974 until January 1997, we selected those
patients with a diagnosis of CAN in a graft biopsy taken more than one year after
transplantation. Graft biopsies were taken between October 1980 and April 1999.
Patients with documented renal graft artery stenosis or ureteral obstruction were
excluded. In our center renal allograft biopsies are only performed on clinical
grounds (either deteriorating graft function or proteinuria exceeding 1 g/24 hrs).
All selected graft biopsies were reviewed by one renal pathologist and evaluated
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according to the Banff 1997 criteria for chronic allograft nephropathy.8 A total of
141 patients were identified initially. Twenty-seven patients were excluded because
the biopsy did not meet the minimal criteria, i.e. containing at least seven glomeruli
and one artery. Patients were also excluded when the graft biopsy showed signs
of co-existing pathology that could influence renal survival (acute rejection in 35
patients, and recurrence of the original renal disease in 7 patients). Finally, 72
patients with histologically confirmed chronic allograft nephropathy could be
evaluated. The medical records of these patients were analyzed with regard to the
following variables: age, original renal disease, donor age and gender, HLA-
mismatches, delayed graft function, immunosuppressive treatment, incidence of
acute rejections, blood pressure, antihypertensive treatment, serum creatinine
levels, and urinary protein excretion. 
Statistical analysis
Values are given as mean ± standard deviation in case of normal distribution or
otherwise as median and range. Statistical analysis was performed using the
Statistical Product and Services Solutions (SPSS) package, version 11.0 (Chicago,
Illinois, USA). Continuous values were analyzed using Student’s t-test or Mann
Whitney U test when appropriate. Categorical values were analyzed using the chi-
square test or Fisher’s exact test when appropriate.
Cox’s proportional hazard model was used for survival analysis. Analysis of the
incidence of graft failure was censored for death of the patient. Both backward and
forward selection was used, with p<0.05, and p<0.10 for retaining/inclusion and
removal of variables, respectively. As the number of variables was too high for
straightforward backward selection, a preliminary selection was carried out and
variables that showed poor univariate association with survival (p>0.15) were
excluded. When necessary, parameters were normalized by logarithmic or square-
root transformation. Sensitivity analyses were carried out in order to evaluate the
robustness of the final model. In these analyses, the impact of the choice of the
criterium for retaining/inclusion and removal of the variables, the choice of
transformation and the influence of collinearity were evaluated. Kaplan Meier-
analysis was used to estimate median survival. A p-value of less than 0.05 (two-
sided) was considered statistically significant.
Results
The patients (45M / 27F) received a kidney graft at an age of 37 ± 16 years. The
donor (39M / 33F) age was 34 ± 19 years. Initial immunosuppressive treatment
included a calcineurin inhibitor in 45 patients. Twenty-five (34.7%) patients
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remained free of acute rejection, 34 (47.2%) had one acute rejection, 10 (13.9%)
had two and 3 (4.2%) had three acute rejection episodes. At 12 months after
transplantation the serum creatinine level was 124 (67-245) µmol/l. 
The index biopsy was taken at 3.3 (1.1-14.0) years after transplantation. The
indication for taking a biopsy was deteriorating graft function in 42 (58%) patients,
proteinuria in 11 (15%) patients, and both in 19 (26%) patients. At the time of
biopsy, the serum creatinine level was 189 (100-501) µmol/l, and 61 (85%) patients
had proteinuria (≥ 0.2 g/10 mmol creatinine). The median urinary protein excretion
in these patients was 3.3 (0.2-16.8) g/10 mmol creatinine. Systolic and diastolic
blood pressure at the time of biopsy were 155 ± 24 mm Hg and 89 ± 11 mm Hg,
respectively. At the time of the biopsy 29 patients were taking a calcineurin inhibitor.
Follow-up time after the index-biopsy was 1.8 (0.1-13.6) years.
On univariate analysis (table 1), histological determinants that significantly
influenced graft survival were the chronic interstitial and chronic tubular score.
Clinical and laboratory factors that significantly influenced graft survival, were: the
serum creatinine level at the time of the biopsy, the relative change in the creatinine
level between 12 months posttransplantation and at the time of the biopsy, mean
systolic and diastolic blood pressure during the first year after the biopsy
(determined with intervals of three months), and RAS-blockade after the biopsy.
The urinary protein excretion at the time of the biopsy showed a strong tendency
to influence renal survival after the biopsy. The use of a calcineurin inhibitor at the
time of biopsy did not influence graft survival. In 7 out of 29 patients using a
calcineurin inhibitor at the time of the biopsy, the calcineurin inhibitor was
withdrawn. This withdrawal did not affect graft survival. The use of other
antihypertensive drugs like calcium channel blockers and β-blockers did not affect
graft survival.
Since ACE-inhibitors and ARBs might have been avoided in patients with a rapidly
deteriorating graft function, we also investigated the effects of these drugs in the
subset of patients, who had a functioning graft for at least 6 months after biopsy
(n=60). Because this analysis yielded the same results as the initial analysis
including all 72 patients, the multivariate analysis was subsequently performed in
all 72 patients. 
Upon multivariate analysis (table 1), the factors that influenced graft outcome were:
the relative change in the creatinine level between 12 months posttransplantation
and at the time of the biopsy, the urinary protein excretion at the time of the biopsy,
the mean diastolic blood pressure during the first year after the index biopsy, and
the use of an ACE-inhibitor or ARB after the biopsy. The histologic parameters did
not independently influence graft outcome.
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Table 1 Cox proportional hazards analysis of factors influencing graft failure
Univariate analysis Multivariate analysis
P Exp(B) 95% C.I. P Exp(B) 95% C.I.
Donor age 0.77 1.00 0.97-1.02
Donor gender 0.67 1.15 0.61-2.18
Gender patient 0.15 1.72 0.83-3.55
S-creatinine at 12 moa 0.36 1.64 0.57-4.68
Ci-score 0.006 1.75 1.17-2.61
Ct-score 0.031 1.54 1.04-2.28
Cv-score 0.41 1.20 0.78-1.85
Cg-score 0.22 1.17 0.91-1.49
Ah-score 0.57 1.09 0.81-1.47
Time between tx-bxa 0.26 0.78 0.50-1.21
Year of biopsy 0.85 0.99 0.92-1.07
S-creatinine at bxa <0.001 7.47 3.00-18.62
Relative change in
S-creatinineb
<0.001 5.80 2.20-15.3 0.003 4.35 1.63-11.61
Proteinuria at bxc 0.056 1.35 1.00-1.84 0.04 1.40 1.02-1.91
Calcineurin inhibitor 0.51 0.80 0.40-1.57
Withdrawal of Csa 0.11 0.69 0.44-1.09
Dm at bx 0.57 1.51 0.36-6.30
RAS-blockade after bx 0.005 0.33 0.15-0.72 0.001 0.25 0.11-0.57
CCB after bx 0.86 0.94 0.48-1.86
-blocker after bx 0.89 1.06 0.48-2.35
Diastolic BP after bxd 0.002 1.06 1.02-1.10 0.002 1.07 1.02-1.11
Systolic BP after bxd 0.005 1.02 1.01-1.04
Mo: months; Ci: chronic interstitial damage; Ct: chronic tubular damage; Cv: chronic vascular
damage; Cg: chronic glomerular damage; Ah: arteriolar hyalinosis; tx: transplantation; bx: graft
biopsy; DM: diabetes mellitus; CCB: calcium channel blocker; a: log-transformation; b: between 12
months posttransplantation and the time of biopsy, log-transformation; c: square-root transformation;
d: mean value during first year after bx.
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Twenty-three patients of our study cohort were treated with an ACE-inhibitor (n=21)
or an ARB (n=2). Four patients started prior to the biopsy, and 19 patients after a
median interval of 3 (1-39) months following the graft biopsy. The ACE-inhibitors or
ARBs were used during 28 (5-77) months. The year of transplantation and the clinical
characteristics of these patients did not differ from those that were never treated
with RAS-blockade (table 2). In the latter group the graft biopsy was taken 3 years
earlier and in the graft biopsy more severe chronic tubular lesions were seen. Initial
immunosuppression after transplantation and immunosuppressive treatment at the
time of the index biopsy did not differ between both groups (table 3). 
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Table 2 Characteristics of patients with or without RAS-blockade
RAS-blockade
(n=23)
No RAS-blockade
(n=49)
P
Year of transplantation 1990 (1974 – 1995) 1987 (1976 – 1995) n.s.
Donor age (yrs) 44 ± 15 29 ± 19 <0.05
Age of patient at tx (yrs) 41 ± 16 36 ± 15 n.s.
Number of acute rejections 0.7 ± 0.7 1.0 ± 0.8 n.s.
S-creatinine at 12 mo (µmol/l) 138 (78-226) 123(67-245) n.s.
Parameters at biopsy
Year of biopsy 1994 (1984 – 1998) 1991 (1980 – 1999) <0.05
Years after tx (yrs) 3.8 (1.2-14.0) 2.9 (1.1-13.5) n.s.
S-creatinine (µmol/l) 171 (115-263) 205 (100-501) n.s.
Proteinuria (g/10 mmol creatinine) 3.4 (0-9.6) 2.0 (0-16.8) n.s.
Systolic BP (mm Hg) 158 ± 22 153 ± 25 n.s.
Diastolic BP (mm Hg) 92 ± 9 87 ± 12 n.s.
Calcineurin inhibitor 8 (36%) 21 (43%) n.s.
Diabetes mellitus 4 (17%) 2 (4%) n.s.
Histologic grading
Ci  2 13 (57%) 38 (78%) n.s.
Ct  2 8 (35%) 32 (65%) <0.05
Cv  2 17 (77%) 30 (73%) n.s.
Ah  2 10 (44%) 14 (29%) n.s.
Cg  2 5 (22%) 15 (31%) n.s.
Tx: transplantation; Ci: chronic interstitial damage; Ct: chronic tubular damage; Cv: chronic vascular
damage; Cg: chronic glomerular damage; Ah: arteriolar hyalinosis; tx: transplantation; bx: graft biopsy
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Haemoglobin level decreased after initiation of RAS blockade, from 7.4 ± 1.0 mmol/l
at baseline to 7.0 ± 1.3 mmol/l at one month (p<0.05), and 6.7 ± 1.5 mmol/l at
six months (p<0.01). RAS-blockade was stopped in one patient after using an ACE-
inhibitor for six months because of anaemia. In the patients not on RAS blockade,
haemoglobin level also decreased, from 7.0 ± 1.2 mmol/l at the time of biopsy, to
6.5 ± 1.4 mmol/l six months later (p<0.01).  At one month after initiation of RAS
blockade serum potassium level increased from 4.1 ± 0.6 mmol/l to 4.6 ± 0.6 mmol/l
(p<0.01), and remained stable thereafter. In none of the patients RAS blockade
had to be stopped due to hyperkalaemia.
At the time of the index biopsy, the number of antihypertensive drugs was not
different for both groups (1.7 ± 1.1 for the RAS blockade group vs 1.4 ± 0.9, n.s.).
In the RAS blockade group the number of antihypertensive drugs increased to 1.9
± 1.1 at six months, 2.3 ± 0.7 at one year and 2.4 ± 0.7 at two years. In the patients
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Table 3 Immunosuppressive and antihypertensive medication in patients with and without
RAS blockade
RAS blockade No RAS blockade P
Baseline immunosuppression
    Azathioprine/prednisone 8 (35%) 19 (39%) n.s.
    CsA/prednisone 14 (61%) 28 (57%) n.s.
    CsA/azathioprine/prednisone 0 1 (2%) n.s.
    CsA/MMF/prednisone 1 (4%) 1 (2%) n.s.
Immunosuppression at bx
    Azathioprine/prednisone 14 (61%) 29 (59%) n.s.
    CsA/prednisone 8 (35%) 16 (33%) n.s.
    CsA/azathioprine/prednisone 0 1 (2%) n.s.
    CsA 1 (4%) 3 (6%) n.s.
Antihypertensive drugsa
-blockers 16 (70%) 34 (70%) n.s.
    Diuretics 12 (52%) 26 (53%) n.s.
    Calcium channel blocker 12 (52%) 25 (53%) n.s.
    Vasodilating agents 1 (4%) 6 (12%) n.s.
    Other antihypertensive drugs 0 1 (2%) n.s.
CsA: cyclosporine; MMF: mycophenolate mofetil; a: used for at least 4 weeks during two years after
the index biopsy.
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not receiving RAS blockade, the number of antihypertensive drugs also increased,
but to a lesser extent, to 1.9 ± 0.8 at one year and 1.9 ± 1.0 at two years after the
biopsy. This resulted in a higher total number of antihypertensive drugs in the
patients on RAS blockade during two years after the index biopsy. The number of
patients using β-blockers, calcium channel blockers, diuretics, and other
antihypertensive drugs was not different between patients using RAS blockade and
patients not on RAS blockade (table 3). 
Baseline systolic blood pressure was 158 ± 19 mm Hg in patients starting on RAS
blockade. At one and six months after initiation of RAS blockade, systolic blood
pressure was 150 ± 23 mm Hg and 152 ± 28 mm Hg, respectively (no significant
differences compared with baseline). Baseline diastolic blood pressure was 90 ± 9
mm Hg in patients starting on RAS blockade. At one and six months after initiation
of RAS blockade, diastolic blood pressure was 87 ± 7 mm Hg and 88 ± 13 mm Hg,
respectively (no significant differences compared with baseline). There was no
difference in time-course of systolic and diastolic blood pressure between patients
on RAS blockade and patients not treated with RAS blockade, during two years
after the index biopsy (p=0.18 and p=0.34, respectively). 
Median baseline proteinuria in patients starting on RAS blockade was 2.1 (0.1 – 9.3)
g/10 mmol creatinine. After initiation of RAS blockade proteinuria decreased to 1.1
(0.1 – 4.3) g/10 mmol creatinine at three months (p=0.021), and 1.2 (0.1 – 6.5)
g/10 mmol creatinine at six months (p=0.086). In the patients not treated with RAS
blockade proteinuria did not change during two years after the index biopsy.    
Median baseline serum creatinine level in patients starting on RAS blockade was
191 (121 – 306) µmol/l. After using RAS blockade for one month serum creatinine
had increased to 210 (128 – 365) µmol/l (p=0.051). At three months after initiation
of RAS blockade no difference in serum creatinine level compared with baseline
was found. 
In patients that were using an ACE-inhibitor or ARB, the median graft survival time
following the biopsy was 6.3 (0.9-10.9) years, as opposed to 1.8 (0.1-6.7) years
in patients not treated with RAS-blockade (p=0.003, Fig. 1). When analyzing only
the patients with a follow-up of at least 6 months after the index-biopsy (n=60),
the difference in renal survival between patients treated with RAS-blockade (6.3
(0.9-10.9) years) and patients not treated with RAS-blockade (2.2 (0.5-13.6) years)
was still significant (p=0.02). In the group of patients that were treated with RAS
blockade, the risk of graft failure was not influenced by the change in proteinuria
between baseline and three months (exp(B)=1.42, 95% C.I. 0.68-2.97; p=0.35),
or between baseline and six months after initiation of RAS blockade (exp(B)=1.07,
95% C.I. 0.65-1.78; p=0.78). Also, the rise in serum creatinine level at one month
after initiation of RAS blockade did not influence graft survival (exp(B)=0.99, 95%
C.I. 0.97-1.01; p=0.33). 
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Discussion
In this retrospective study in patients with biopsy-proven CAN, we demonstrate that
RAS-blockade results in increased graft survival. The effect of treatment with an
ACE-inhibitor or ARB in our study is consistent and strong. Exclusion of patients with
loss of graft function within 6 months after the biopsy did not alter the results.
Moreover, baseline clinical characteristics of patients that were treated with RAS-
blockade, including blood pressure, urinary protein excretion and presence of
diabetes, were not different from the patients that were not treated with these drugs.
The only observed differences between both groups were the score for chronic tubular
damage, and the year of biopsy. The latter differed by merely three years, while the
time interval between transplantation and biopsy was similar in both groups.
Moreover, in multivariate analysis neither the histological score nor the year of biopsy
influenced graft survival. Taken together, although we have to admit that the
retrospective nature of the study may have biased the results in some way, we feel
that it is unlikely that selection bias can fully explain the observed benefit of RAS
blockade. Our study thus strengthens the conclusion of Lin et al.9 In a retrospective
analysis in renal transplant patients with biopsy-proven CAN, these authors observed
a trend towards slowing the progression of renal insufficiency in patients using either
an ACE-inhibitor or an ARB. In Lin’s study CAN was graded mild in approximately
50% of cases, and approximately 40% of patients also showed signs of acute
rejection in the biopsy, which may explain the more moderate efficacy of RAS
blockade in their patients.
Our data support that RAS blockade can be safely used in renal transplant patients,
even when moderate renal insufficiency is present. Unexpected rises of serum
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creatinine, anaemia, and hyperkalaemia were not a major problem, a conclusion
also drawn by Stigant et al. who have evaluated RAS blockade in patients with well
preserved graft function.7
We did not observe a difference in blood pressures after renal biopsy in the two
patient groups, although the patients on RAS blockade used more antihypertensive
drugs than patients not treated with RAS blockade. It is therefore unlikely that the
beneficial effect of RAS blockade was largely mediated by blood pressure reduction.
Nevertheless, we found that the level of blood pressure per se was a predictor of
renal function deterioration. This is in agreement with studies demonstrating that
hypertension is an independent risk factor for CAN.3 Also, hypertension is an
independent risk factor for cardiovascular disease, which is the leading cause of
death in renal transplant recipients.10 Treatment of hypertension therefore is
important, not only for maintaining graft function, but also for reducing
cardiovascular morbidity. 
Initiation of RAS blockade was followed by a firm reduction of proteinuria of more
than 50%. Comparable degrees of reduction of proteinuria have been observed in
other studies addressing the antiproteinuric effects of ACE-inhibitors, especially in
patients with secondary forms of focal segmental glomerulosclerosis.11 The large
effect of RAS blockade on graft survival, with graft half-life almost increasing
threefold, may seem rather incredible. However, similar renoprotective effects have
been reported in patients with IgA nephropathy (end point reached in 13% vs
57%),12 and in the GISEN study in patients with non-diabetic proteinuric renal
diseases (relative risk reduction 2.32).13 Although high levels of proteinuria were
associated with reduced graft survival, we could not demonstrate a relation between
the decrease in proteinuria after start of RAS blockade and graft survival. This could
be related to lack of power.
Although the magnitude of the protective effect of RAS blockade in our patients
must be interpreted with caution in view of the retrospective nature of the study,
it is safe to conclude that RAS blockade, in particular ACE-inhibition, which we mainly
have used, does not exert any untoward effect in patients with CAN, as might have
been anticipated based on some animal and human data. In a study investigating
the effect of ACE-inhibitors or ARBs in a rat-model of CAN, chronic RAS-blockade
by both drugs resulted in preservation of glomerular morphology in the absence
of proteinuria, but intimal hyperplasia was enhanced, especially when the RAS
blockade was initiated early after transplantation.6 In human studies ACE-inhibitors
increased the risk of restenosis after coronary stent implantation, especially in
patients with the DD genotype for the angiotensin-I converting enzyme deletion
allele polymorphism.14 These observations suggest that during repair of the
endothelium, shortly after an insult like recent ischemia-reperfusion injury or after
recent stenting, blockade of the formation of angiotensin II might have unwanted
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effects on the vascular patency. During rejection episodes donor endothelium is
replaced by endothelial cells of the recipient.15 Apparently, recovery of endothelial
injury in patients with CAN is not negatively influenced by administration of ACE-
inhibitors at the indicated time periods.
The mechanisms of the renoprotective effects of ACE-inhibitors and ARBs are
debated. Possible mechanisms include a reduction of intraglomerular capillary
pressure due to efferent arteriolar vasodilation, a decreased production and/or
expression of growth factors like transforming growth factor (TGF)-β,16 or a
reduction of the activity of the plasminogen activator inhibitor type I (PAI-I), a
fibrogenic and fibrinolytic mediator that has been associated with the occurrence
and rate of progression of CAN.17 Although the renoprotective effects of both ACE-
inhibitor and ARB are mainly achieved by their shared antiproteinuric effect, their
mechanism of action is not entirely similar. ACE-inhibitors block the formation of
angiotensin II, thereby blocking the stimulation of both the AT1 and AT2 receptor
(angiotensin II receptor type 1 and 2). ARBs result in blockade of the AT1 receptor,
whereas the AT2 receptor can still be stimulated. Stimulation of the AT2 receptor
by angiotensin II counteracts many effects of the AT1 receptor, and may be beneficial
for the prevention of restenosis after coronary angioplasty.18 Furthermore,
angiotensin II stimulates the release of PAI-I. Treatment with the ACE-inhibitor
ramipril resulted in a sustained reduction of the plasma level of PAI-I, whereas
losartan only caused a temporary reduction.19 The clinical significance of these
differences has not been fully elucidated, but the renoprotective effect of ACE-
inhibitors and ARBs in nondiabetic renal disease and in type 2 diabetes with incipient
nephropathy is considered to be comparable.20
In contrast to others,2 we did not find an improvement of the course of renal function
upon discontinuing the use of calcineurin inhibitors. This lack of effect might be
related to limited power, since discontinuation of calcineurin inhibitors was only
performed in 7 patients.
In summary, our data indicate that RAS-blockade by an ACE-inhibitor or ARB in
biopsy-proven CAN results in increased graft survival. In view of the limited
treatment options for CAN, this finding is of importance and needs confirmation by
a prospective randomized trial.    
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Chapter 9
Summary and conclusions
During the past three decades, improved immunosuppression has resulted in
reduced acute rejection rates and improved early allograft survival. However, in
order to improve long-term renal graft survival, other factors apart from preventing
acute rejections have to be addressed.
Death with functioning graft and chronic allograft nephropathy (CAN) are the most
frequently encountered causes of late allograft failure, both accounting for
approximately 40% of allograft losses. Cardiovascular disease is the main cause
of death in renal transplant patients and is caused by both conventional
cardiovascular risk factors like hypertension and dyslipidemia, and by cardiovascular
risk factors related to renal disease or renal dysfunction, including proteinuria,
hyper-homocysteinemia, proteinuria, hyperuricemia, left ventricular hypertrophy,
hyperparathyroidism, hypercalcemia and hyperphosphatemia, that are present in
the vast majority of renal transplant patients. 
After death with functioning graft, chronic allograft nephropathy is the most common
cause of graft failure beyond the early posttransplantation period. Both immunologic
and nonimmunologic factors are implicated in the pathogenesis of CAN. The risk
of CAN is associated with acute rejections, pre-existent damage of the implanted
kidney graft, the use of nephrotoxic drugs, and cardiovascular risk factors resulting
in transplant vasculopathy. Recurrent glomerulonephritis is not a major cause of
allograft loss. However, since graft survival is increasing and the incidence of
recurrent glomerulonephritis rises over time, the relative importance of recurrence
as the cause of allograft loss is likely to increase in the near future.
The aim of the studies presented in this thesis was to gain more insight in several
determinants of long-term renal graft and patient survival, and to search for
methods to improve both.
Calcineurin inhibitors play a dual role in the outcome of renal transplantation. The
introduction of cyclosporine has resulted in an important reduction in the incidence
of acute rejections after renal transplantation. However, due to the nephrotoxicity
bw.van leeuwen  12-07-2005  10:34  Pagina 125
and the unfavourable cardiovascular risk profile associated with cyclosporine, the
beneficial effect of cyclosporine on long-term renal graft and patient survival has
appeared to be disappointingly low. Although tacrolimus and cyclosporine are both
calcineurin inhibitors, their mechanism of action is not entirely similar, and their
side—effects also differ. In chapter two, we have analyzed the effects of
randomized conversion from cyclosporine to tacrolimus in chronic stable renal
transplant patients, with special emphasis on a wide range of cardiovascular risk
factors. During a follow-up of six months, conversion from cyclosporine to
tacrolimus resulted in a reduction in systolic and diastolic blood pressure, reduced
levels of serum total and LDL cholesterol levels, serum triglyceride levels, and
apolipoprotein B levels. Post-hoc analysis showed that the changes in blood pressure
were only significant at three months after conversion to tacrolimus. No increment
in the incidence of new-onset diabetes mellitus occurred. These changes in blood
pressure and serum lipid levels resulted in a reduction in the Framingham risk score.
Subgroup analysis revealed that the improvement in the cardiovascular risk score
was only apparent in patients not using statins, indicating that the reduction of the
serum LDL cholesterol level is the main factor contributing to the improvement.
Conversion from cyclosporine to tacrolimus not only reduced serum LDL cholesterol
levels, but also resulted in a significant though small reduction in oxidizability of
the LDL particle. No significant influence of conversion to tacrolimus on the
homocysteine levels could be demonstrated. 
In chapter three, the effects of conversion from cyclosporine to tacrolimus on
renal graft function after two years of follow-up are presented. In patients
converted to tacrolimus, renal graft function remained stable during two years of
follow-up, whereas the serum creatinine gradually rose in the cyclosporine group,
from 142 ± 48 µmol/l to 157 ± 62 µmol/l (p<0.001). Conversion from cyclosporine
to tacrolimus resulted in a sustained reduction in systolic and diastolic blood
pressure during two years of follow-up, and a sustained improvement in the serum
LDL cholesterol and triglyceride levels, leading to a reduction in the Framingham
risk score from 5.7 ± 4.3 to 4.8 ± 5.3 at two years after conversion (p<0.05). No
increment in the incidence of new-onset diabetes mellitus was found. Finally,
conversion to tacrolimus resulted in decreased scores for occurrence of and distress
due to side-effects compared with patients on cyclosporine. 
In conclusion, conversion from cyclosporine to tacrolimus in stable renal transplant
patients is beneficial with respect to renal graft function, the cardiovascular risk
profile, and the experience of side-effects. The improvements in renal graft function
and cardiovascular risk score upon conversion to tacrolimus are small, but they
are achieved without putting the patient at risk for developing an acute rejection
or new-onset diabetes mellitus, and therefore, in case of long-term maintenance
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immunosuppression after renal transplantation by means of a calcineurin inhibitor,
for most patients tacrolimus is preferable compared with cyclosporine. 
Recurrence of focal segmental glomerulosclerosis is characterized by the early onset
of severe proteinuria after renal transplantation, and results in graft loss in 40 –
50% of cases. Prognosis of recurrent FSGS can be improved by early start of
plasmapheresis treatment. Therefore, it is important to differentiate proteinuria
due to recurrent FSGS from proteinuria due to preservation injury. In chapter four,
we have determined the time-course of proteinuria related to ischemia-reperfusion
damage during the first five days after transplantation in patients not suffering
from end-stage renal disease due to FSGS. Immediately after transplantation, a
massive non-selective high and low molecular weight proteinuria occured, indicative
of glomerular and tubular damage. This proteinuria rapidly decreased to slightly
elevated levels beyond 24 hours after transplantation, and thereafter proteinuria
rarely exceeded 1 gram per day. These data indicate that during the first 24 hours
after renal transplantation recurrent FSGS and ischemia-reperfusion damage can
not be differentiated. Thereafter, proteinuria exceeding 1 gram/day  more likely
results from recurrent FSGS.
The hemolytic uremic syndrome is characterized by microangiopathic hemolytic
anemia, thrombocytopenia and acute renal insufficiency. The etiology of HUS is
diverse. The classical or diarrhea-associated form of HUS is predominantly seen in
children, whereas the atypical or non-diarrhea-associated form mainly occurs in
adults. In chapter five we report on the outcome of renal transplantation in 35
patients suffering from HUS. After first renal transplantation in 17 patients with
adult-onset HUS, definite and probable recurrence of HUS occurred in seven (41%)
and three (18%) cases, respectively. Recurrence developed after a median time
of 30 days, resulting in graft loss in all cases, after a median time of 8 days. The
use of cyclosporine as part of the initial immunosuppressive therapy increased the
risk of recurrence (Odds ratio 7.3, 95% C.I. 1.6 – 33.3, p=0.01)). In 18 patients
with childhood-onset HUS no definite and one (6%) probable recurrence occurred.
In both adult-onset and childhood-onset HUS the incidence of acute rejections was
increased, compared with matched controls (Odds ratio  1.52, 95% C.I. 1.05 –
2.19, p<0.05, and 1.88, 95% C.I. 1.34 – 2.62, p<0.001, respectively). This resulted
in a poor one-year graft survival in patients with adult-onset HUS (29%), whereas
the one-year graft survival in patients with childhood HUS was comparable with
their matched controls. 
The outcome of renal transplantation in 43 patients with end-stage renal disease
due to pauci-immune small vessel vasculitis and anti-GBM glomerulonephritis is
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described in chapter six. After a mean follow-up of 62 ± 57 months no renal
recurrence was observed, and only one extrarenal relapse in a patient with
Wegener’s granulomatosis. Graft and patient survival rates were comparable with
a matched control group. Patients with pauci-immune small vessel vasculitis or anti-
GBM glomerulonephritis developed more malignancies than their matched controls
(Odds ratio 2.82, 95% C.I. 1.18 – 6.71, p=0.02), especially skin malignancies (Odds
ratio 4.50, 95% C.I. 1.35 – 15.15, p=0.006).
In chapter seven, the outcome of renal transplantation in 23 patients with systemic
lupus erythematosus is analyzed after a mean follow-up of 74 ± 72 months. One
(4%) patient developed a probable recurrence of lupus nephritis at 61 months after
transplantation, resulting in graft loss two months later. Two other patients had
signs of extra-renal SLE disease activity at 6 and 17 months after transplantation,
respectively. Patient and graft survival was not different for SLE patients and their
matched controls.
After death with functioning graft, chronic allograft nephropathy is the leading cause
of late allograft failure, with only limited treatment options. Blockade of the renin-
angiotensin system decreases progression in diabetic and non-diabetic proteinuric
renal disease, but the effect on CAN was unclear. In chapter eight we describe
the results of a retrospective analysis of the effect of RAS-blockade on renal survival
in 72 patients with biopsy-proven CAN. Multivariate analysis revealed that graft
outcome was influenced by the change in the serum creatinine level between one
year posttransplantation and at the time of the index-biopsy, the urinary protein
excretion, mean diastolic blood pressure after the index biopsy, and RAS blockade.
Renal graft survival in patients on RAS blockade was 6.3 (0.9-10.9) years, as
opposed to 1.8 (0.1-6.7) years in patients not on RAS blockade (p=0.003). Although
the magnitude of the protective effect of RAS blockade in patients with CAN must
be interpreted with caution in view of the retrospective nature of the study, the
effect of RAS blockade on renal graft survival in our study is consistent and strong. 
Conclusions
Conversion from cyclosporine to tacrolimus in chronic renal transplant patients with
a stable graft function results in a persistently stable graft function, as opposed to
a gradual decline in renal function in patients remaining on cyclosporine.
Furthermore, systolic and diastolic blood pressure are reduced, and the lipid profile
is improved, with a reduction in serum total and LDL cholesterol and serum
triglycerides, and a slightly reduced oxidizability of the LDL-particle. When using
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tacrolimus at low standard maintenance dose, the conversion from cyclosporine to
tacrolimus bears no risk of acute rejection and does not lead to an increased
incidence of diabetes mellitus, at least not in our study population, mainly
consisting of Caucasian patients. For most renal transplant patients, tacrolimus
might be the drug of choice, when long-term treatment with a calcineurin inhibitor
is indicated.
During the first 24 hours after renal transplantation recurrent FSGS and ischemia-
reperfusion damage can not be differentiated by the degree of proteinuria.
Thereafter, proteinuria exceeding 1 gram/day  more likely results from recurrent
FSGS.
In adult-onset HUS the recurrence-rate and the incidence of acute rejections are
high, resulting in poor graft survival. Cyclosporine as part of the initial
immunosuppressive regimen increases the risk of recurrence. 
Adult-onset HUS patients belong to the renal patients with the poorest
transplantation results. Due to the low incidence of adult-onset HUS as cause of
end-stage renal disease, evidence-based treatment aimed at preventing recurrent
disease and acute rejections is difficult to attain. 
In patients with pauci-immune small vessel vasculitis and anti-GBM
glomerulonephritis, the rate of renal recurrence is very low. Graft and patient
survival do not differ from the general renal transplant population. The risk of 
skin malignancies is increased, probably due to the longstanding use of
immunosuppressive medication prior to transplantation.
In patients with end-stage renal disease due to systemic lupus erythematosus, the
risk of recurrent renal disease is small (4%), and patient and graft survival do not
differ significantly from that in the general renal transplant population. 
Firm evidence for treatment of CAN is lacking. In our retrospective analysis RAS
blockade by an ACE-inhibitor or ARB in biopsy-proven CAN resulted in increased
graft survival, and RAS blockade in patients suffering from varying stages of renal
insufficiency was generally well tolerated. Confirmation of these results in a
prospective randomized trial is needed. In view of the beneficial effect of RAS
blockade in our retrospective study, initiation of RAS blockade should be considered
in all patients with biopsy-proven CAN, after the exclusion of a transplant artery
stenosis.
129
Summary and conclusions
bw.van leeuwen  12-07-2005  10:34  Pagina 129
bw.van leeuwen  12-07-2005  10:34  Pagina 130
Chapter 10
Samenvatting en conclusies
Gedurende de laatste decennia heeft verbetering van immunosuppressieve
medicatie geleid tot een vermindering van de incidentie van acute rejecties na
niertransplantatie en tot een verbeterde 1-jaars transplantaat-overleving. Voor
verbetering van de lange termijn transplantaat-overleving zijn echter, naast
preventie van acute rejecties, ook andere factoren van belang.
Overlijden van de patiënt met nog functionerende transplantaatnier, en daarnaast
chronische allograft nefropathie zijn de meest voorkomende oorzaken van laat
transplantaatnierfalen. Cardiovasculaire aandoeningen vormen de voornaamste
doodsoorzaak bij niertransplantatie-patiënten.  Bij het ontstaan van het vaatlijden
bij niertransplantatie-patiënten spelen zowel de conventionele risicofactoren, zoals
hypertensie en hyperlipidemie een rol, als ook een aantal factoren die gerelateerd
zijn aan de nieraandoening of aan de verminderde nierfunctie, zoals proteinurie,
hyperhomocysteinemie, hyperuricemie, linker ventrikel hypertrofie, hyperpara-
thyreoidie, hypercalciëmie en hyperfosfatemie.
Na overlijden met functionerende transplantaatnier is chronische allograft
nefropathie de meest voorkomende oorzaak van laat verlies van de
transplantaatnierfunctie. Zowel immunologische als niet-immunologische factoren
zijn betrokken bij de ontwikkeling van chronische allograft nefropathie. Het risico
op chronische allograft nefropathie wordt verhoogd door acute rejecties, schade
aan de transplantaatnier voorafgaande aan de transplantatie, nefrotoxische
medicatie, en vaatpathologie van de transplantaatnier. Recidief van het grondlijden
in de transplantaatnier is tot dusverre geen frequent voorkomende oorzaak van
laat transplantaatnierfalen. Echter, de kans op recidief van het grondlijden neemt
toe in de loop van de tijd na transplantatie, en de gemiddelde transplantaatnier-
overleving neemt toe, zodat de kans op nierfalen ten gevolge van een recidief van
het grondlijden in de toekomst waarschijnlijk zal toenemen. 
De studies die gepresenteerd worden in dit proefschrift hebben tot doel om meer
inzicht te verkrijgen in een aantal determinanten van lange termijn
transplantaatnier- en patiënt-overleving.
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Na de introductie van cyclosporine is de incidentie van acute rejecties sterk
gereduceerd, vergeleken met initiële immunosuppressie met azathioprine. Ondanks
deze sterke reductie in de incidentie van acute rejecties is het effect van
cyclosporine op de lange termijn transplantaat-overleving minimaal, hetgeen wordt
gerelateerd aan de nefrotoxiciteit van cyclosporine en daarnaast het nadelige effect
van cyclosporine op een aantal cardiovasculaire risicofactoren, zoals de bloeddruk
en de lipiden. Tacrolimus is net als cyclosporine een calcineurine-remmer, echter
het werkingsmechanisme van beide calcineurine-remmers is niet volledig identiek,
en ook de bijwerkingen vertonen verschillen. In hoofdstuk 2 zijn de effecten van
gerandomiseerde conversie van cyclosporine naar tacrolimus in chronische stabiele
niertransplantatie-patiënten na een follow-up van 6 maanden geanalyseerd, met
speciale nadruk op de cardiovasculaire risicofactoren. Conversie naar tacrolimus
resulteerde in een lagere systolische en diastolische bloeddruk, en reducties in de
serum-concentraties van het totaal en LDL-cholesterol, de triglyceriden en het
apolipoproteine B. Post-hoc analyse toonde dat de verandering in bloeddruk alleen
3 maanden na conversie naar tacrolimus significant was. Conversie naar tacrolimus
resulteerde niet in een verhoogde incidentie van de-novo diabetes mellitus. De
reductie in bloeddruk en serum lipiden resulteerde in een reductie van de
Framingham risico score. Subgroep analyse toonde dat de verbetering van de
cardiovasculaire risico-score alleen optrad bij de patiënten die geen statines
gebruikten. Conversie van cyclosporine naar tacrolimus leidde niet alleen tot een
kwantitatieve afname van de LDL-cholesterol concentratie, maar leidde ook tot een
significante maar kleine afname in de oxideerbaarheid van de LDL-partikels, en
daarmee tot een afname van de atherogeniciteit van het LDL-cholesterol. Conversie
naar tacrolimus resulteerde niet in een verbetering van het homocysteine-gehalte.
In hoofdstuk 3 worden de effecten van conversie van cyclosporine naar tacrolimus
bij chronische stabiele niertransplantatie-patiënten na twee jaren follow-up
beschreven. Na conversie naar tacrolimus bleef de transplantaatnierfunctie
gedurende twee jaren stabiel, terwijl bij de patiënten die cyclosporine bleven
gebruiken het serum-creatinine geleidelijk steeg, van 142 ± 48 µmol/l naar 157
± 62 µmol/l (p<0.001). Conversie naar tacrolimus leidde tot aan aanhoudende
reductie in systolische en diastolische bloeddruk, en een aanhoudende verbetering
in het serum LDL-cholesterol en triglyceride-gehalte, leidend tot een verlaging van
de Framingham risico score van 5.7 ± 4.3 naar 4.8 ± 5.3 twee jaren na conversie
(p<0.05). Conversie naar tacrolimus resulteerde niet in een toename in incidentie
van de-novo diabetes mellitus. Na conversie van cyclosporine naar tacrolimus traden
bijwerkingen minder frequent op en werden als minder hinderlijk ervaren. 
Samenvattend is conversie  van cyclosporine naar tacrolimus bij chronische stabiele
niertransplantatiepatiënten gunstig voor de transplantaatnierfunctie, het
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cardiovasculaire risicoprofiel en het optreden van bijwerkingen. De mate van
verbetering van de nierfunctie en het cardiovasculaire risicoprofiel is klein, maar
dit wordt bereikt zonder een verhoogd risico op acute rejecties en zonder toename
van de incidentie van diabetes mellitus. Om deze redenen is voor de meeste
niertransplantatiepatiënten in geval van onderhouds-immunosuppressieve
behandeling middels een calcineurine-remmer tacrolimus gunstiger dan
cyclosporine.
Een recidief van focale segmentale glomerulosclerose (FSGS) in de transplantaatnier
wordt gekenmerkt door het kort na transplantatie optreden van ernstige proteinurie.
Het leidt tot transplantaatverlies in 40 tot 50 % van de gevallen. De prognose van
een recidief FSGS kan worden verbeterd door snelle start met plasmaferese
behandeling. Voor een snelle en adekwate diagnose van recidief FSGS dient
proteinurie ten gevolge van recidief FSGS te worden onderscheiden van proteinurie
t.g.v. preservatieschade van de transplantaatnier. In hoofdstuk 4 hebben we het
tijdsbeloop van proteinurie ten gevolge van ischemie-reperfusie schade gedurende
de eerste 5 dagen na transplantatie bepaald bij patiënten die als oorspronkelijke
nieraandoening geen FSGS hadden. Direkt na transplantatie treedt een massale
niet-selectieve proteinurie met hoog en laag moleculair gewicht op, duidend op
glomerulaire en tubulaire schade. Deze proteinurie neemt snel af, en na 24 uren
na transplantatie is de proteinurie in het algemeen lager dan 1 gram per etmaal. 
Concluderend kan gedurende de eerste 24 uren na niertransplantatie recidief FSGS
niet gedifferentieerd worden van ischemie-reperfusie schade. Na 24 uren
posttransplantatie is proteinurie van meer dan 1 gram per etmaal suggestief voor
een recidief FSGS.
Het hemolytisch uremisch syndroom (HUS) wordt gekenmerkt door micro-
angiopathische hemolytische anemie, thrombocytopenie en acute nierinsufficiëntie.
Er zijn verschillende oorzaken voor het optreden van HUS. De klassieke of diarree-
geassociëerde vorm van HUS wordt voornamelijk gezien bij kinderen, terwijl de
atypische of niet-diarree geassociëerde vorm met name bij volwassenen optreedt.
In hoofdstuk 5 beschrijven we de transplantatie-resultaten bij 35 patiënten met
grondlijden HUS. Van 17 patiënten met op volwassen leeftijd ontstane HUS,
ontwikkelden zeven (41%) patiënten een zeker en drie (18%) patiënten een
waarschijnlijk recidief in de transplantaatnier. Dit recidief ontstond na een mediane
tijdsduur van 30 dagen na transplantatie, en leidde in alle gevallen tot transplantaat-
verlies, na een mediane tijd van 8 dagen. Het gebruik van cyclosporine direkt na
transplantatie verhoogde het risico op het optreden van een recidief (Odds ratio
7.3, 95% C.I. 1.6 – 33.3, p=0.01). Van 18 patienten met HUS, ontstaan op de
kinderleeftijd, ontwikkelde geen enkele patiënt een zeker en één (6%) patiënt een
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mogelijk recidief in de transplantaatnier. Bij zowel op volwassen leeftijd als op
kinderleeftijd ontstane HUS was de incidentie van acute rejecties na
niertransplantatie verhoogd, vergeleken met gematchte controle-patiënten (Odds
ratio respectievelijk 1.52, 95% C.I. 1.05 – 2.19, p<0.05, en 1.88, 95% C.I. 1.34
– 2.62, p<0.001). De 1-jaars transplantaat-overleving bij patiënten met op
volwassen leeftijd ontstane HUS was sterk gereduceerd ten opzichte van gematchte
controlepatiënten en bedroeg 29%.  Bij patiënten met op kinderleeftijd ontstane
HUS was de 1-jaars transplantaat overleving vergelijkbaar met de gematchte
controlepatiënten. 
In hoofdstuk 6 worden de niertransplantatie-resultaten bij 43 patiënten met als
grondlijden pauci-immuun vasculitis en anti-GBM glomerulonefritis beschreven. Na
een gemiddelde follow-up van 62 ± 57 maanden werd geen recidief in de
transplantaatnieren gezien. Eén patiënt met de ziekte van Wegener ontwikkelde
een alleen extrarenaal gelocaliseerd recidief. Transplantaat- en patiëntoverleving
bij patiënten met als grondlijden pauci-immuun vasculitis en anti-GBM
glomerulonefritis waren vergelijkbaar met de gematchte controlegroep. Patiënten
met pauci-immuun vasculitis en anti-GBM glomerulonefritis ontwikkelden wel meer
maligniteiten vergeleken met de controlepatiënten (Odds ratio 2.82, 95% C.I. 1.18
– 6.71, p=0.02), m.n. huidmaligniteiten (Odds ratio 4.50, 95% C.I. 1.35 – 15.15,
p=0.006).
In hoofdstuk 7 worden de niertransplantatie-resultaten bij 23 patiënten met
systemische lupus erythematosus beschreven. Eén (4%) patiënt ontwikkelde 61
maanden na transplantatie een waarschijnlijk recidief van lupus nefritis, uiteindelijk
na 2 maanden resulterend in terminale nierinsufficiëntie. Twee (8%) andere
patiënten vertoonden tekenen van extra-renale SLE activiteit op 6 en 17 maanden
na niertransplantatie. Transplantaat- en patiëntoverleving bij SLE patiënten was
vergelijkbaar met de controlepatiënten.
Na overlijden met functionerende transplantaatnier is chronische allograft
nefropathie de voornaamste oorzaak van laat transplantaatnierfalen. Blokkade van
het renine-angiotensine systeem (RAS) vertraagt de progressie bij diabetische en
niet-diabetische nieraandoeningen met proteinurie, maar het effect bij chronische
allograft nefropathie was onduidelijk. In hoofdstuk 8 beschrijven we de resultaten
van een retrospectieve analyse van het effect van RAS-blokkade op de transplantaat-
overleving bij 72 patiënten met histologisch bewezen chronische allograft
nefropathie. Multivariate analyse toonde dat de transplantaat-overleving werd
beinvloed door het verschil in serum creatinine waarde tussen 1 jaar na trans-
plantatie en ten tijden van het nierbiopt, de mate van proteinurie, de gemiddelde
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diastolische bloeddruk na de index biopsie, en RAS-blokkade. De transplantaat-
overleving bij patiënten die een ACE-remmer danwel een angiotensine-2-receptor
blokker gebruikten was 6.3 (0.9 – 10.9) jaren, en bij patiënten die deze medicatie
niet gebruikten 1.8 (0.1 – 6.7) jaren (p=0.003). Bevestiging van deze resultaten
in een prospectieve gerandomiseerde studie is aangewezen.
Conclusies
Conversie van cyclosporine naar tacrolimus bij chronische stabiele niertransplan-
tatiepatiënten leidt tot een stabiele transplantaatnierfunctie gedurende twee jaren
follow-up, terwijl bij de patiënten die cyclosporine blijven gebruiken de
transplantaatnierfunctie geleidelijk achteruit gaat. Daarnaast treedt er een verlaging
op van de systolische en diastolische bloeddruk, en een verbetering van het lipiden-
profiel, met een reductie van de serum LDL-cholesterol en triglyceriden-concentratie
en een lichte vermindering van de oxideerbaarheid van de LDL-partikels. Bij
conversie van cyclosporine naar tacrolimus is het risico op het optreden van een
acute rejectie zeer klein en de kans op het optreden van de-novo diabetes mellitus
is, althans in een studie-populatie bestaande uit met name kaukasische patiënten,
niet vergroot. Voor de meeste niertransplantatiepatiënten verdient tacrolimus de
voorkeur boven cyclosporine, in geval van langdurige immunosuppressie middels
calcineurine-remmers.
Gedurende de eerste 24 uren na niertransplantatie kunnen recidief FSGS en
ischemie-reperfusie schade niet worden gedifferentiëerd middels de mate van
proteinurie. Na 24 uren posttransplantatie is proteinurie van meer dan 1 gram per
etmaal suggestief voor recidief FSGS.
Bij op volwassen leeftijd ontstane HUS zijn na niertransplantatie de incidenties van
recidief HUS en  van acute rejecties hoog, leidend tot een slechte transplantaat-
overleving. Het gebruik van cyclosporine als initiëel immunosuppressivum direkt
na transplantatie verhoogt het risico op een recidief HUS in de transplantaatnier.
Patiënten met op volwassen leeftijd ontstane HUS behoren tot de nierpatiënten
met de slechtste niertransplantatieresultaten. Het ontwikkelen van evidence-based
richtlijnen gericht op de preventie van recidief HUS in de transplantaatnier en
reductie van acute rejecties wordt bemoeilijkt door de lage incidentie van het
ziektebeeld HUS.
Bij patiënten met pauci-immuun vasculitis en anti-GBM glomerulonefritis is de kans
op een recidief van het grondlijden in de transplantaatnier klein. De transplantaat-
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en patiëntoverleving is vergelijkbaar met de gemiddelde niertransplantatie-
populatie. De kans op de ontwikkeling van een huidmaligniteit is verhoogd,
waarschijnlijk ten gevolge van het langdurige gebruik van immunosuppressiva
voorafgaande aan de niertransplantatie.
Bij patiënten met terminale nierinsufficiëntie ten gevolge van systemische lupus
erythematosus is de kans op recidief lupus nefritis gering (4%), en de transplantaat-
en patiëntoverleving komt overeen met de gemiddelde niertransplantatie-populatie. 
Er is geen evidence-based behandeling van chronische allograft nefropathie. In onze
retrospectieve analyse blijkt RAS-blokkade middels een ACE-inhibitor danwel een
angiotensine–receptor blokker bij histologisch bewezen chronische allograft
nefropathie te leiden tot een toename van de transplantaat-overleving. Bevestiging
van deze resultaten in een prospectieve studie is aangewezen. Gezien het gunstige
effect van RAS-blokkade dient het gebruik van deze medicatie bij alle patiënten
met een histologisch aangetoonde chronische allograft nefropathie te worden
overwogen, na uitsluiting van een transplantaatnier-arteriestenose.
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Bij mijn verkenningen naar factoren die de lange-termijns overleving van
transplantaatnieren beïnvloeden heb ik met veel mensen samengewerkt. Ik wil al
deze mensen, ook diegenen die ik niet met naam noem, van harte bedanken voor
hun hulp en loyaliteit.
Allereerst wil ik de patiënten bedanken voor hun medewerking aan de tactics-studie. 
Het was voor veel patiënten niet eenvoudig om na de vele medische perikelen die
voorafgaan aan het bereiken van een stabiele chronische transplantaatnierfunctie,
toch weer deel te nemen aan een conversie-onderzoek, waarbij de vertrouwde
immunosuppressieve medicatie zou worden gewijzigd. Toch hebben uiteindelijk veel
patiënten deelgenomen aan de studie, met als voornaamste motivatie om te willen
bijdragen aan verdere toename van kennis betreffende een behandeling die hen zo
goed geholpen had. De grote en betrouwbare inzet van de deelnemende patiënten
heeft uiteindelijk geleid tot een succesvolle afronding van de tactics-studie.
Rob Koene. Toen ik als student in 1990 voor het eerst op de afdeling nierziekten
kwam, viel me je grote enthousiasme voor de nefrologie op. Je enthousiasme was
aanstekelijk, en toen ik mijn project op de afdeling afgerond had, wist ik dat ik meer
wilde. Gelukkig heb je me de kans geboden om op jouw afdeling de opleiding tot
nefroloog te volgen, en daarnaast te starten met dit promotie-onderzoek. Je bent
je tijd ver vooruit in het faciliteren van de combinatie van werk en kinderen, en part-
time werken houdt bij jou geen tweederangs carrière in. Ik wil je bedanken voor je
vertrouwen, en met name voor het voorbeeld dat je hebt gegeven. Ik hoop dat ik
met hetzelfde plezier mijn werk gedurende de komende jaren kan blijven doen.
Jack Wetzels. Je encyclopedische kennis en je scherpzinnige inzichten zijn alom
bekend. Even een praatje maken met jou leverde altijd een aantal A-viertjes op met
associatieve ideeën, waarvan ik me dan op mijn kamer in wanhoop afvroeg hoe ik
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die nu weer allemaal moest realiseren. Wat een vertrouwen moet je in me hebben
gehad. Nou, het is gerealiseerd, ik ben er tevreden over, hopelijk jij ook. 
Luuk Hilbrands. Je was mijn begeleider bij mijn eerste projectje op de afdeling
nierziekten, en je hebt een belangrijke bijdrage geleverd aan dit promotie-
onderzoek. Ik ben je dankbaar voor je snelle en heldere correcties van mijn
manuscripten, waarbij je gelukkig altijd weer mijn problemen met tegenwoordige,
voltooid en onvoltooid verleden tijd haarfijn kon ontwarren. En natuurlijk dank voor
het lenen van je kamer in de vele buiten-kantoortijd uren.
Marjo van Helden. Jij weet als geen ander gezellig kletsen en hard werken te
combineren. Je was je gewicht in goud waard. Oase van relativering en daarnaast
ook nog vol met beproefde opvoedingstips. Je bent om al deze uiteenlopende redenen
de beste research-verpleegkundige die ik me had kunnen wensen.
Hans Boots, Maarten Christiaans, Gerry Ligtenberg, Pieter Vos en Joke
Roodnat, mede-onderzoekers van de tactics-trial uit Maastricht, Utrecht en
Rotterdam. Bedankt voor jullie trouwe inbreng in de studie, het includeren van
patiënten, het aanleveren van de data, en met name ook jullie geduld bij het wachten
op de manuscripten. Het uiteindelijke resultaat mag er zijn.  
George Borm, wat was ik blij met je hulp bij de statistiek. Jouw inbreng resulteerde
in gedegen en ook begrepen analyses, en daarnaast veel plezier bij het verrichten
hiervan. 
Philip Moons, je hebt me ingewijd in de wereld van de RIDIT analyse, waaraan ik
vele uren heb gerekend. Gelukkig behield jij het overzicht beter dan ik. Je hulp bij
de analyse van de bijwerkingen scores was dan ook essentiëel, waarvoor mijn dank.
Pièrre Demacker, door en door vertrouwd met de lipiden-wereld. Je bent van groot
belang geweest bij de bepaling van de lipiden, als onderdeel van tactics 1. Je bent
een echte wetenschapper, en dat was te merken aan de manier waarop je het eerste
tactics manuscript corrigeerde. Het eerste en beslist zwaarste stuk om te schrijven.
Jouw grondige en kritische beoordeling van het manuscript heeft me zeer geholpen.
Anneke Geurts, Helga Toenhake en Heidi Hak, laborantes van het
endocrinologielab en het lipidenlab. Voor een clinicus met klinische studies is de
afstand tot het laboratorium groot. Mijn voornaamste inbreng bij de
laboratoriumbepalingen bestond uit het afdraaien van het bloed, het invriezen van
de monsters en vervolgens het aanleveren in het laboratorium. Gelukkig zorgden
jullie voor de rest. Zorgvuldig en betrouwbaar, en altijd op tijd. Heel fijn.
Joop Göertz, bedankt voor je expertise bij de gedifferentiëerde bepaling van de
verschillende proteïnes in de urine en voor je snelle verwerking van de monsters.
Uiteindelijk was daardoor dit project het eerste project dat ik volledig kon afronden.
Eric Steenbergen, het HUS manuscript stond in de steigers, maar het kon pas
worden afgerond na de revisie van de nierbiopten en het verrichten van de C4d-
kleuringen. Gelukkig vond je tijd om naast je gewone werkzaamheden deze biopten
138
Dankwoord
bw.van leeuwen  12-07-2005  10:34  Pagina 138
te beoordelen. Ik voelde me bijna bezwaard als ik weer een stapel preparaten op
je bureau schoof. Ik ben je zeer dankbaar voor je hulp.
Karel Assmann, je was betrokken bij de studie naar chronische allograft
nefropathie. Ondanks je drukke bezigheden heb je toch nog tijd gevonden om alle
biopten te reviseren. Twee weken voordat je van je welverdiende rust ging genieten
was het werk klaar. Deze inzet van jouw kant verplichtte mij natuurlijk ook tot
voltooiing van het project, hetgeen resulteerde in het artikel over het gunstige effect
van RAS-blokkade bij chronische allograft nefropathie.   
Jeroen Deegens, je hebt veel werk verzet voor het recurrens-onderzoek bij SLE-
en pauci-immuun vasculitis patiënten. Inmiddels ben je goed op weg met je eigen
promotie-onderzoek en ben je begonnen met de opleiding tot nefroloog. Bedankt
voor je hulp en de prettige samenwerking.
Peggy du Buf, we werken al weer ruim twee jaren in een inmiddels beproefde en
goed functionerende duobaan in Breda. De wetenschap dat er goed voor mijn
patiënten wordt gezorgd tijdens mijn afwezigheid heeft gezorgd voor de
noodzakelijke rust om dit proefschrift af te ronden. 
Pa en Ma. Lieve ma, van alle mensen die ik hier bedank heb jij de meest cruciale
rol gespeeld bij de totstandkoming van dit boekje. Ik kon altijd een beroep op je
doen om voor de kinderen te zorgen, aanvankelijk met name op de vaste
oppasvrijdag en later gedurende de lange logeerwerkweekenden. De wetenschap
dat de kinderen bij jou in vertrouwde handen waren gaf mij de rust om door te
werken.
Lieve pa, ik had je zo graag het eindresultaat van mijn werk laten zien. Niet omdat
ik er zo trots op ben, maar om je te laten zien dat het af is. Je had gelijk, het was
een  beetje veel allemaal, maar ik heb nu eenmaal je vasthoudendheid geërfd. Ik
zal je missen bij de promotie. 
Lieve Loes en Femke. Jullie komst heeft ons leven veranderd. Jullie bruisende en
sprankelende aanwezigheid is relativerend, inspirerend en uitputtend. Als opvoeden
voorleven is, dan hoop ik dat ik het goed heb gedaan. Het beeld van een mama die
het altijd druk heeft is misschien wel heel actueel en realistisch, maar het is toch
niet mijn ideaalbeeld. Ik verheug me op een lange en meer rustige toekomst met
jullie.
Guido, zou het dan nu eindelijk gaan gebeuren, samen rustig op de bank? 
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